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Immunomodulatory Effects of Novel Therapies for Stroke
Aaron A. Hall
Abstract
Each year, approximately 795,000 people suffer a new or recurrent stroke.
About 610,000 of these are first attacks, and 185,000 are recurrent attacks
(Carandang et al. 2006). Currently the only FDA approved treatment for
ischemic stroke is recombinant tissue plasminogen activator (Alteplase) (Marler
and Goldstein 2003). Unfortunately its use is restricted to a short, 4.5 hour, time
window. Two promising therapies in the treatment of stroke at delayed
timepoints are human umbilical cord blood cells (HUCBC) and the sigma
receptor agonist DTG
The first series of experiments were conducted to characterize the effects
of sigma receptors on various aspects of microglial activation. Sigma receptor
activation suppresses the ability of microglia to rearrange their actin cytoskeleton,
migrate, and release cytokines. Stimulation of sigma receptors suppressed both
transient and sustained intracellular calcium elevations associated with microglial
activation. Further experiments showed that sigma receptors suppress microglial
activation by interfering with increases in intracellular calcium.
An ex vivo organotypic slice culture (OTC) model to was utilized to
characterize the efficacy of sigma receptor activation and HUCBC therapy in

x

mitigating neurodegeneration in ischemic brain tissue in the absence of the
peripheral immune system. HUCBC but not DTG treatment reduced the number
of degenerating neurons and the production of microglia derived nitric oxide in
slice cultures subjected to oxygen glucose deprivation (OGD) back to levels seen
in the normoxia controls.
The final experiments were performed to characterize the effects of the
peripheral immune system on the brain over time and identify changes mediated
by HUCBC and DTG. Labeled splenocytes were found in spleen, blood, and
thymus, but not in the brain in appreciable numbers at any timepoint. IL10 and
IFNγ levels were found to significantly increase by 96hours post MCAO. This
increase in IL10 and IFNγ expression was blocked HUCBC or DTG.
The experiments described here have shed light on the molecular
mechanisms of stroke injury and the relative targets that DTG and HUCBC
therapies exploit. These data suggest that the neuroprotection achieved by DTG
or HUCBC is mediated by the ability of these treatments to modulate the
peripheral immune systems response to injury.
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Chapter 1
Background and Significance

Clinical impact of stroke
Each year, approximately 610,000 people suffer an initial stroke, and
185,000 additional people have a recurrent attack. Every 40 seconds someone in
the United States has a stroke making this disease a leading cause of death and
disability in this country (Carandang et al. 2006). While the stroke death rates
have decreased due to better treatment and hospital care, the lack of effective
treatments to improve functional recovery has caused a concomitant increase in
the number of people disabled by this disease. The estimated direct and indirect
cost of stroke in the U.S. is nearly $ 68.9 billion per year (Lloyd-Jones et al.
2009), while the burden on families is unquantifiable and severe.
Approximately 87% of stroke cases are due to an ischemic (embolic or
thrombotic) stroke with the remainder being hemorrhagic in nature (Lloyd-Jones
et al. 2009). Ischemic strokes can be further subcategorized into small vessel
and large vessel strokes based on the size of the artery occluded. Small vessel
strokes, or lacunar strokes, occur when one of the small penetrating arteries
which branch from larger vessels becomes occluded causing a small (<15mm)
lesion in the subcortical regions of the brain (Norrving 2008). This type of lesion
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accounts for 25% of ischemic strokes and frequently acute stroke symptoms are
not evident with the infarct only presenting as a small hole or “lacunae” upon
necropsy. When acute stroke symptoms do present, they normally present with
one of five classical “lacunar syndromes”. These include: pure motor
stroke/hemiparesis, ataxic hemiparesis, dysarthria/clumsy hand, pure sensory
stroke, and mixed sensorimotor stroke. These symptoms typically manifest when
the lesion damages major subcortical structures such as the internal capsule,
basis pontis, thalamus, or the pons. As these strokes do not impact the cortex
they do not present with pure cortical symptomology such as aphasia, neglect,
and visual field defects (Fisher 1982). Clinical prognosis in the near term for
patients with lacunar infarcts is favorable as the acute (<30day) survival rate is
~97%, and the chronic (1year and beyond) survival rate is 87% (Bejot et al. 2008;
Sacco et al. 2006).
Acute large vessel strokes typically occur when atherosclerotic plaques
develop inside the large arteries feeding the brain causing them to become
stenotic and easily occluded by blood clots. These blood clots either break off of
the plaque (thrombotic) or are generated elsewhere in the body (embolic). As
these large vessels supply a greater portion of the blood supply to the brain the
corresponding infarcts are larger and injure both cortical and subcortical
structures. This leads to pathologies which can include all lacunar symptoms in
addition to cortical symptomology such as aphasia, neglect, and visual field
defects. Clinical prognosis in the near term for patients with large vessel infarcts
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is poorer than lacunar pathology as the acute (<30day) survival rate is 85%, and
the chronic (1year and beyond) survival rate is 65-70% (Carandang et al. 2006).
Small vessel and large vessel strokes respond similarly to currently
available interventions such as recombinant tissue plasminogen activator (rTPA)
and aspirin suggesting a common pathological response to the injury (Norrving
2008). Functional MRI studies in large vessel strokes have determined that the
infarct increases in size by 21% reaching a maximal value by 74 hrs and
subsequently decreases in size during days 5-7 (Schwamm et al. 1998). Similar
effects on infarct size evolution have been observed in lacunar strokes further
suggesting that a common response by the body to these ischemic injuries
exists. Furthermore similar kinetics have been observed rats following middle
cerebral artery occlusion (MCAO) (Newcomb et al. 2006).
The body’s response to ischemic injury is multifaceted and changes over
time. Traditional imaging techniques in humans can provide details on the gross
changes in infarct size, neuronal excitability, and cerebral blood flow. Although
new ligands for positron emission tomography (PET) (Baron 2001) and functional
magnetic resonance imaging (fMRI) techniques are beginning to shed light on
the human response to ischemia (Baron 2002), animal models have been
required to answer important questions about the cellular response to ischemia.

Animal models of stroke
Rodent models of stroke have been critical to increasing our
understanding of the pathology and progression of ischemia induced brain
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lesions (Traystman 2003; Willing 2009). Murine and rat models of stroke are
commonly used and can be separated into two categories: global ischemia, in
which total perfusion to the brain is blocked, and focal ischemia, in which
perfusion of only part of the brain is inhibited. Focal ischemia includes
transluminal middle cerebral artery occlusion in which an embolus is advanced
into the MCA occluding blood flow, and distal middle cerebral artery occlusion in
which the MCA is occluded by a clot which is either injected into the middle
cerebral artery (Kaneko et al. 1985) or formed by the photolysis of a dye such as
Rose Bengal (Markgraf et al. 1993). Global ischemia is a model which more
closely mimics the neuronal damage incurred following a heart attack, while focal
ischemia more closely resembles an ischemic stroke.
The distal middle cerebral artery occlusion technique lends itself to the
study of thrombolytic therapy as the artery is occluded by a blood clot; however
this technique is more traumatic to the animal as a craniotomy must be
performed (Kaneko et al. 1985). The transluminal middle cerebral artery
occlusion technique is a commonly employed surgical stroke model. Its
advantages include the relative ease at which both permanent as well as
transient ischemic events can be induced by merely leaving in or withdrawing the
suture used to block the MCA, as well as reproducibility of the infarct size. Due
to the large size of the infarct produced, this model lends itself to investigations of
neuroprotective treatments. Furthermore, this stroke model closely mimics large
vessel strokes which account for the majority of strokes in the human condition.
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Experimental rodent models of stroke have yielded a trove of information
concerning stroke pathophysiology. There has, however, been substantial
difficulty translating therapeutic efficacy in rodents into improved clinical
outcomes in stroke patients. This is due in part to inherent differences between
human patients and rodent models. Humans are gyrencephalic organisms (have
convoluted cortices) while rodents are lissencephalic (have smooth cortices).
Humans also have a far greater proportion of white matter than rodents (Dewar
et al. 1999; Hagberg et al. 2002). MRI imaging studies have demonstrated a
correlation between lesions which impact the descending motor tracts, which are
composed of white matter, and poorer function outcome in patients (Dawes et al.
2008; Pineiro et al. 2000). White matter dysfunction in ischemic injury is
understudied compared to neuron rich grey matter and is a likely source of the
disparity seen between infarct volume reductions in rodents and functional
improvements in patients.
Another confound between animal models and the human condition is in
the age and condition of the subject. Stroke patients are typically elderly and
often present with underlying disease states such as high blood pressure,
diabetes, atherosclerosis, and heart disease. Animal models, on the other hand,
typically utilize healthy adolescent male subjects. Advanced age and underlying
pathology can reduce the efficacy in humans of treatments which were protective
in rat models.
Perhaps the most important source of discrepancy between animal and
human models of stroke lies not in the model itself but in the experimental design
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utilizing the model. Many researchers neglect to take into consideration the
human conditions when designing in vivo experiments. Administration of
experimental neuroprotectants at the time of or prior to the onset of ischemia
may be useful for understanding disease pathology but are impractical for use in
the clinic. Patients typically arrive at the ER many hours after stroke, and are in a
condition not modeled by the treatment paradigm. Indeed many of the preclinical
studies targeting excitotoxicity such as NMDA antagonism and calcium channel
blockade succumbed to this flaw and the treatments were ineffective clinically.

Failed therapies for stroke
Attempts to develop neuroprotective treatments for stroke have yielded
disappointing results thus far. Therapeutic interventions can be grouped into two
broad categories: therapies targeting neurons and the early processes implicated
in their demise, and therapies which target the delayed glial/immune response to
stroke. The vast majority of trials to date have focused on reducing the buildup
of intracellular calcium, neuronal firing, and free radicals. These therapies were
developed in order to combat a phenomenon called excitotoxicity which is
thought to damage neurons (Dirnagl et al. 1999). Neuronal damage in this model
is caused by the overactivation of NMDA channels on penumbral neurons due to
high levels of glutamate and aspartate released from the ischemic core. This
increased NMDA receptor activation causes calcium to enter the cell where it can
activate proapoptotic signaling cascades, cause free radical buildup, and trigger
neuronal death (Dirnagl et al. 1999). Multiple steps in this excitotoxic process
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have been targeted for intervention such as NMDA receptor antagonism
(Selfotel) (Davis et al. 2000), AMPA receptor antagonism (ZK200775) (Elting et
al. 2002), calcium channel blockade (Flunarizine) (Limburg and Hijdra 1990),
GABA activation (Clomethiazole) (Lyden et al. 2001), sodium channel blockade
(fosphenytoin), potassium channel opening (BMS-204352), and free radical
scavengers (Lubeluzole) (Diener et al. 2000). While these therapies were
effective in preclinical animal studies, none showed significant improvement
clinically. Some of the reasons include a short therapeutic time windows (<1 hr)
for efficacy, and undesirable side effects such as hallucination and psychosis
(NMDA receptor antagonists) (Davis et al. 2000) and severe reductions in blood
pressure (calcium channel blockers) (Horn et al. 2001).
Trials which target the glial/immune response to stroke have also been
unsuccessful. The earliest of these trials involved the use of high dose
dexamethasone to suppress the inflammatory response following stroke (Mulley
et al. 1978). Later trials have focused on preventing immune cell infiltration of
the infarct by administering antibodies or other recombinant proteins to bind
adhesion molecules and prevent immune cell infiltration following stroke (1999;
2001; Lees et al. 2003). All of these trials failed to show therapeutic efficacy in
clinical trials and all but UK-279276 (neutrophil inhibitory factor) significantly
increased post stroke mortality as well.
The failures presented here suggest that our knowledge of post-ischemic
pathology is incomplete. Therefore it is imperative that novel therapeutic
strategies be developed, not only to improve the clinical setting, but also to
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improve the understanding of the underlying mechanisms of this disease. To
develop these therapies the underlying processes which occur following ischemia
must be elucidated.

The local response to ischemia
Rapidly following the obstruction of blood flow to the brain the tissue
parenchyma undergoes significant changes. The area of brain tissue that
receives blood supply primarily from the occluded vessel and has a greater than
75% loss in perfusion is called the core of the infarction. Neurons in the core of
the infarct are under the greatest metabolic stress and are the least likely to be
responsive to neuroprotective treatments (Lipton 1999). The area surrounding
the core of the infarction which receives partial blood perfusion from collateral
blood vessels is known as the penumbra. Cells in the penumbra while under
some metabolic demand are further stressed by stroke associated phenomena
such as anoxic depolarization and inflammation which can cause their
destruction at delayed timepoints. The penumbra is the primary target for
neuroprotective therapies since it accounts for a significant area of the infarct and
does not die as quickly as the core.
When the artery supplying blood flow to brain tissue becomes obstructed,
loss of ATP necessary for the maintenance of ionic homeostasis, leads to rapid
calcium accumulation in ischemic neurons (Lipton 1999). This process leads to
increased in neuronal firing causing a phenomenon known as anoxic
depolarization. Anoxic depolarization in non-ischemic brain does not cause
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neuronal loss, and when induced 3 days prior to ischemia can cause
neuroprotection via ischemic preconditioning mechanisms (Obrenovitch 2008).
In ischemic brain, however, the increased neuronal firing exacerbates the
metabolic demand and further decreases energy stores in ischemic neurons
leading to their compromise (Takano et al. 1996). The increases in intracellular
calcium levels induce intracellular phospholipases, proteases, and
endonucleases lead to the functional compromise of the neuron. This results in
the production of inflammatory lipid peroxidation products such as prostanoids
which can exacerbate membrane permeability and lead to cytotoxic edema
(Dirnagl et al. 1999). This leakiness of the neuronal plasma membrane also
results in the release of ATP into the extracellular space. This release of ATP
leads to the early activation of the resident microglia and astrocytes inducing the
acute inflammatory response.

Endogenous microglial activation during the early inflammatory response
Microglia are the resident macrophages of the brain, which under normal
conditions are kept in a quiescent state. Resting microglia exhibit a ramified
morphology in vivo characterized by fine processes expressing chemosensitive
receptors (Streit et al. 2004). In an uninjured brain these cells are involved
essential functions such as synaptic pruning, debris removal, defense against
infection, and neurotrophic support (Streit et al. 2005).
Studies using GFP-labeled microglia in vivo demonstrated that microglial
processes are highly mobile and quickly move towards ATP released by injured
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neurons (Davalos et al. 2005; Haynes et al. 2006). Microglia can then assist the
damaged neuron by sequestering glutamate (van Landeghem et al. 2001) in
addition to releasing neurotrophins such as BDNF (Coull et al. 2005) and TGFβ
(da Cunha et al. 1997; Lehrmann et al. 1998). In ischemia where the number of
injured neurons is large the microglia will then withdraw their processes,
assuming an amoeboid “activated” phenotype (see Garden et al (Garden and
Moller 2006) for review), and can secrete cytotoxins such as nitric oxide, reactive
oxygen species, and prostaniods (Gibson et al. 2005). These cells can also
promote the inflammatory response by secreting pro-inflammatory cytokines
such as IL1β and TNFα (Allan and Rothwell 2001; Dirnagl et al. 1999). Whether
this causes neuronal death directly however is uncertain as ablation of microglia
exacerbates ischemic injury (Lalancette-Hebert et al. 2007).
This release of inflammatory cytokines was originally thought to
exacerbate ischemia induced injury based on in vitro studies where direct
application of these IL1β and TNFα (Jara et al. 2007; Thornton et al. 2006) killed
cultured neurons, and in vivo studies where neutralization of these cytokines by
endogenous receptor antagonist (Relton et al. 1996) or soluble receptor (IL1β
and TNFα respectively) reduced infarct volumes. Whether these effects are due
to direct neuronal toxicity are unclear as IL1β amplifies the initial immune
infiltration by stimulating microglia and astrocytes to produce MMP9. In vivo
studies using TNF receptor knockout mice have demonstrated that microglial
derived TNFα is neuroprotective via activation of the of the p55 subunit of the
TNF receptor (Lambertsen et al. 2009). Furthermore ablation of microglia
10

exacerbates ischemic injury (Lalancette-Hebert et al. 2007). In early ischemic
injury, the release of IL1β, TNFα, and IL6 by microglia is extremely important in
the transition from a local immune response to a global immune/stress response
(Zheng and Yenari 2004).

Activation of the neuro-immune and hypothalamic pituitary adrenal axes
Local inflammation has both beneficial and deleterious effects on ischemic
lesions. When the local inflammation activates the peripheral immune system,
however, a much larger inflammatory response is elicited causing collateral
destruction of the peri-infarct regions (Offner et al. 2006). Therefore, the
peripheral inflammatory response to brain injury is tightly regulated. The brain
communicates with the immune system largely via direct innervation of lymphoid
tissues and humeral control provided by the hypothalamic-pituitary-adrenal axis
(HPA axis) (Chrousos 1995). Inflammatory cytokines IL1β, TNFα, and IL6
released in response to brain injury stimulate centers in the locus ceruleus to
induce neural sympathetic activation, as well as cause the release of CRH in the
hypothalamus (Chrousos 1992). IL1β and TNFα stimulate the production of IL6
which in turn inhibits their production. IL6 acts synergistically with glucocorticoids
to induce the release of acute phase reactants from the liver including C-reactive
protein. C-reactive protein and IL6 are elevated in the serum of patients with
ischemic stroke and are correlated with poorer outcomes.
Stimulation of either the locus ceruleus or the HPA axis activates the other
based on neural crosslinks between the lateral paraventricular nucleus and the
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locus ceruleus (Saper et al. 1976). Once these systems are activated, the
resulting release of epinephrine from the adrenal glands in addition to the direct
secretion of norepinephrine into the lymphoid organs by sympathetic nerve fibers
results in a “sympathetic storm” (Chamorro et al. 2007). The increase in
circulating catecholamines in addition to increased plasma cortisol
concentrations suppress immune cell function. This acute stress response alters
the morphology of the two peripheral lymphoid organs known to be involved in
the progression of stroke: the thymus and the spleen (Elenkov et al. 2000).
The thymus and the spleen are densely innervated by noradrenergic
nerve terminals (Anagnostou et al. 2007), and upon induction of CNS ischemia
become reduced in size (Offner et al. 2006; Vendrame et al. 2006). Multiple
groups have associated this decrease in thymus and spleen size with profound
leucopenia and an increased susceptibility to infection based a lack of IFNγ
producing T-cells (Prass et al. 2003; Yilmaz et al. 2006). This
immunosuppression, while likely helpful at reducing permanent brain injury, can
be reversed by administration of beta-adrenergic blockers such as propranolol
(Meisel et al. 2005; Prass et al. 2006). The Offner group postulated that the
decrease in spleen and thymus size was due to mass apoptotic cell death in
these organs based on TUNEL immunoreactivity (Offner et al. 2006). Recent
work in our lab has demonstrated that the spleen shrinkage is due to activation of
alpha1 adrenergic receptors located on the smooth muscle capsule and this
shrinkage can be blocked by prophylactic administration of prazosin, an alpha1
receptor antagonist.
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Human blood samples taken during the PANTHERIS trial (Klehmet et al.
2009) and in other clinical stroke settings (Urra et al. 2009), confirmed the
increased catecholamine levels in stroke patients in addition to the leucopenia .
It is still unclear whether increased susceptibility to infection in the clinical setting
is a direct product of this immunosuppression, or a product of stroke induced
complications. These complications include dysphasia, which is known to
increase pneumonia incidence, and the need for a urinary catheter, which is
associated with increased urinary tract infections (UTIs). Pneumonia and UTIs
are common stroke associated nosocomial infections and are the leading causes
of delayed (>5 day) stroke mortality (Aslanyan et al. 2004).

The role of the peripheral lymphoid organs in stroke
The induction of such profound immunosuppression indicates that the
peripheral lymphoid organs can exacerbate ischemic injury. The spleen in
particular plays a critical role in the response to ischemic injury. Cell tracking
studies of intravenously (i.v.) injected of human umbilical cord blood cells
(HUCBC) into rats receiving MCAO identified the spleen and the infarct as the
primary targets of this therapy (Vendrame et al. 2004a). Studies comparing i.v.
injection to striatal injection of HUCBC showed that i.v. injection was superior
suggesting that the splenic actions of these cells were important for the
therapeutic benefit of this treatment (Willing et al. 2003). Splenectomy
significantly reduces ischemic injury in multiple organ systems including liver
(Okuaki et al. 1996), GI tract (Savas et al. 2003), and kidney (Jiang et al. 2007).
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Recent results in our lab show that splenectomy prior to stroke reduces infarct
volume by 80% (Ajmo et al. 2008); similar to levels of protection seen in HUCBC
therapies (Vendrame et al. 2004b). This significant protective effect in multiple
tissue types indicates that the spleen contributes to ischemic injury in a tissue
type independent manner, and this response likely is responsible for infarct
expansion and degeneration of the penumbra.

The peripheral leukocyte response to ischemia
Upon induction of ischemia, endothelial cells in the infarct begin the
process of recruiting peripheral leukocytes into the damaged parenchyma by
upregulating ICAM1 and ICAM2 (Lindsberg et al. 1996; Wang et al. 1994). The
first leukocyte subtype to infiltrate the brain is neutrophils, a small
polymorphonuclear cell which begins to adhere to the endothelium between 1
and 6 hours following ischemia onset and invade the infarct beginning 6 hours
after adherence (Kochanek and Hallenbeck 1992). These cells express selectins
and integrins which enable them to extravate between the endothelial cells and
begin degrading the basal lamina through the secretion of matrix
metalloproteinase and other proteases (Jean et al. 1998; Matsuo et al. 1994).
These proteases not only further weaken the blood brain barrier but also
contribute to the ensuing inflammation by activating chemokines such as MCP-1
and SDF-1a (Overall et al. 2002) along with proinflammatory cytokines such as
IL1β (Schonbeck et al. 1998) and TNFα (Gearing et al. 1994). These
chemoattractants further serve to recruit peripheral leukocytes such as
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macrophages, T and B lymphocytes, and dendritic cells to the infarcted tissue.
Once within the parenchyma, neutrophils release reactive oxygen and nitrogen
species in addition to various enzymes such as myeloperoxidase and elastase
which are normally sequestered in their cytoplasmic granules (Jean et al. 1998).
These observations of potential neurodestructive capabilities of
neutrophils, however, must be weighed against the results from clinical trials
which show no added clinical benefit to blocking neutrophil migration. These
studies used several differing molecular targets to achieve this such as:
neutrophil inhibitory factor (a recombinant glycoprotein with selective binding to
the CD11b integrin of MAC-1 (CD11b/CD18)), inhibition of leukocyte adhesion by
antibodies against ICAM (Enlimomab Acute Stroke Trial), or CD18 (HU23F2G
Anti-Adhesion to Limit Cytotoxic Injury trial). The antibody studies resulted in
increased morbidity and mortality and both trials using this rationale were
discontinued due to safety concerns.
Much of the toxicity attributed to neutrophils was based on the activity of
the enzyme myeloperoxidase which produces highly reactive oxygen species
and is correlated with both increased infarct volume and poorer outcome after
stroke (Kitamura et al. 1997). Myeloperoxidase is expressed not only by
neutrophils, but by all cells of myeloid lineage including macrophages (Lagasse
and Weissman 1994). In vivo imaging of myeloperoxidase activity showed peak
activation 3 days after MCAO, a timepoint which is well after the initial influx of
neutrophils and correlates with peak macrophage aggregation (Weston et al.
2007). There is evidence in the literature that macrophages phagocytose
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neutrophils in the ischemic infarct, with 50% of neutrophils in the infarct being
engulfed three days after MCAO (Meszaros et al. 1999; Weston et al. 2007).
This engulfment is one of the primary mechanisms by resolution of neutrophil
based inflammation, with macrophages preferentially clearing aging neutrophils
first (Lagasse and Weissman 1994).
Macrophage accumulation following ischemia is highly correlated with the
production of the chemokine MCP-1 (Wang et al. 1995). This chemokine is
produced and secreted as a protein precursor by astrocytes and neurons (Che et
al. 2001; Gourmala et al. 1997). This chemokine is activated and released by
proteases such as plasmin (Sheehan et al. 2007) and is detected beginning at 6
hours following transient ischemia (Yamagami et al. 1999). This timepoint
correlates with neutrophil infiltration and is likely related to production of MMPs
by these cells. MCP-1 expression increases and reaches peak levels between 2
and three days following MCAO which correlates with the influx of macrophages
to the infarct (Wang et al. 1995). MCP-1 also induces the expression of ICAM-1
mRNA in kidney models (Giunti et al. 2006; Viedt et al. 2002) and likely further
increases invasion of the brain parenchyma by peripheral immune cells.
Ameboid macrophages are the most abundant immune cells in the infarct
following MCAO (Stoll et al. 1998). Whether these cells are microglia which have
transformed into an amoeboid phenotype or are infiltrating monocytes is
impossible to determine immunohistochemically or morphologically. Studies in
which peripheral macrophages are labeled with iron particles and tracked
following photochemically induced MCAO suggest that peripheral macrophage
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recruitment is a delayed phenomenon which peaks at 5 days following MCAO.
(Kleinschnitz et al. 2003) These finding suggest that the macrophages which are
observed at 3 days following MCAO are microglial in origin. Histochemical
studies following ischemia, however, do suggest that a population of CD8+
macrophages do infiltrate the CNS within 48 hours following ischemia, though
their function is not known (Jander et al. 1998).
Regardless of their origin, amoeboid macrophage levels peak by 3 days
following MCAO and remain elevated for weeks following insult. These cells are
involved in tissue destruction, turnover of extracellular matrix, removal of cell
debris, and wound healing (Schilling et al. 2005). Depletion of peripheral
macrophages using clodronate liposomes has no effect on infarct volume
suggesting that these cells do not directly induce ischemic damage (Schroeter et
al. 1997). Sheets of “foamy” macrophages have been described in infarcts of
stroke patient’s brains at delayed timepoints further confirming the phagocytic
and tissue removal functions of these cells (Petroff et al. 1992). Macrophage
depletion impairs remyelination after injury (Kotter et al. 2001), demonstrating a
complex role in infarct development and resolution.
While cells of the innate immune system are the most numerous found in
the infarct, cells of the adaptive immune system play an important role in stroke
pathology. T and B lymphocytes infiltrate the infarct along with neutrophils and
macrophages and contribute to the inflammation and tissue destruction that
occurs there. Under normal conditions the brain is considered an immune
privileged organ. When T-cells enter the parenchyma following ischemia, they
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are exposed to new antigens such as myelin basic protein (MBP) and myelin
oligodendrocyte glycoprotein (MOG) which they have not been exposed to during
the self selection process. Experiments in which mice were tolerized to these
proteins prior to MCAO showed a significant reduction in infarct volume
demonstrating that adaptive immunity plays a significant part in the post stroke
inflammatory response (Frenkel et al. 2003; Gee et al. 2008). Severe combined
immunodeficient (SCID) mice and recombinase activating gene 1 (Rag-/-)
knockout mice, which lack functional T-and B- lymphocytes, had significantly
smaller infarcts when compared to their wild type litter mates following transient
MCAO (Yilmaz et al. 2006). Further studies in which mice which lacked CD4+
and CD8+ T-lymphocytes were subjected to transient MCAO showed that these
T-lymphocyte subtypes are important for the induction of tissue damage following
ischemia (Yilmaz et al. 2006).
B-lymphocytes are recruited to the brain following MCAO. Their role once
there may be a protective one, as mice which lack B-lymphocytes did not have
reduced infarct volumes suggesting that these cells may not directly participate in
the acute phase destruction of tissue (Yilmaz et al. 2006). Additionally in human
patients, lower B-cell counts, but not other leukocyte subpopulations, in the blood
correlated with adverse outcomes upon admission and at 2 days after stroke
implying a protective effect of these cells (Urra et al. 2009). As interactions
between B-cells and antigen presenting cells elicit an anti-inflammatory humeral
response, reduced numbers of B-cells may correlate with increased inflammation
and increased brain damage (Harling-Berg et al. 1999). Alternatively increased
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brain damage may induce a stronger stress response from the HPA axis causing
increased cortisol levels increasing β2-adrenergic receptors which can result in
increased apoptosis of B-cells in response to catecholamines.

Current therapies for stroke
While much has been learned about the mechanisms by which stroke
damage occurs, the design of new therapeutics for ischemic injury has been
fraught with failure. The only currently available interventions for stroke sufferers
are thrombolytics such as rTPA and mechanical clot removal (Marler and
Goldstein 2003). These therapies are aimed solely at restoring blood flow to the
infarcted tissue, have no direct neuroprotective properties, and must be
administered at similar timepoints. In order to provide benefit these therapies
must be administered at a very early timepoint prior to the induction of the
inflammatory response. The numbers of patients, who arrive at the hospital,
receive a CT scan to rule out hemorrhagic stroke, and be administered therapy
within the 3-6 hour time window are small, representing only 3-5% of stroke
sufferers (Marler and Goldstein 2003).
Tissue plasminogen activator is a serine protease produced by
macrophages and endothelial cells, which converts plasminogen to plasmin, a
fibrin cleaving enzyme (Teesalu et al. 2002). Plasminogen, a zymogen secreted
by the liver, binds fibrin and is incorporated into blood clots. Fibrin is a protein
found in blood clots which is composed of chains of fibrin monomers linked
through the action of coagulation factor III. Once plasminogen is converted to
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plasmin, it cleaves fibrin, releasing soluble fragments and exposing lysine
residues which the plasmin binds to prior to cleaving again.
Of those patients whom are candidates for rTPA, only 13% had an
improved outcome compared to placebo (Albers et al. 2004). This benefit must
also be weighed against the significantly increased risk for bleeding, a process
called hemorrhagic transformation (Toni et al. 1996). In this process, rTPA can
activate proMMP9 present in neutrophils granules leading to further degradation
of the basal lamina and increased risk for bleeding (Cuadrado et al. 2008).
Mechanical clot disruption is a nonenzymatic method of restoring blood flow by
physically removing a clot. In this method, a catheter is introduced into the
blocked artery and a device (frequently a coil) is inserted into the clot, the
catheter is then removed pulling the clot free, and allowing recanalization (Noser
et al. 2005). This technique can be used in conjunction with rTPA and has
shown promising results in phase 2 clinical trials (Kim et al. 2006). Phase three
clinical trials such as the IMSIII trial are underway and should shed light on the
therapeutic efficacy of this technique.

Therapeutic targets for stroke at delayed timepoints
Until recently it was believed that neurons died very rapidly following
stroke onset by these excitotoxic mechanisms. This was based on the
observation of neurons which had become pyknotic and expressed various
markers for apoptosis such as Annexin V, cleaved caspase 3, and TUNEL stains.
This belief was challenged on observations that HUCBC could reverse these
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apoptosis markers resulting in a 50-70% reduction in infarct volume when
administered up to 48 hours after undergoing permanent MCAO (Vendrame et al.
2004a). HUCBC are the mononuclear fraction of cells isolated from umbilical
cord blood collected after birth. This cell population includes approximately 1%
CD34+ stem cells with the remainder being lymphocytes at varying stages of
development. HUCBC administration is associated with profound
neuroprotective and anti-inflammatory effects when administered in animal
models of a variety of disease states such as ALS (Garbuzova-Davis et al. 2003),
Alzheimer’s disease (Nikolic et al. 2008), Parkinson’s disease (Ende and Chen
2002), spinal crush injury (Saporta et al. 2003), and stroke (Newcomb et al.
2006; Vendrame et al. 2004a). While this therapeutic does have a stem cell
component, cell tracking studies demonstrated that very few of these cells
actually implanted into the damaged tissue suggesting that this is not a cell
replacement therapy (Vendrame et al. 2004a).
Further studies in our lab have identified the sigma receptor agonist 1, 3di-o-tolylguanidine (DTG) as a therapy which substantially reduces infarct volume
when administered 24 hours following MCAO (Ajmo Jr et al. 2006). The
identification of a second unrelated therapeutic which is neuroprotective at
delayed timepoints suggests that there is an underlying mechanism which can be
harnessed to provide neuroprotection at a time when a majority of stroke patients
can be seen and treated. Furthermore, this suggests that excitotoxicity and
anoxic depolarization are not as damaging as once thought. This finding has
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important implications with respect to the treatment of hypoxic ischemic injury in
other disease paradigms.
Other treatments which suppress infarct volumes at delayed timepoints
include ethyl pyruvate (Yu et al. 2005) and granulocyte colony stimulating factor
(Sehara et al. 2007),. These treatments also have potent anti-inflammatory
properties and show functional recovery in addition to reduced infarct volumes.

Sigma receptor agonists as a therapy for stroke
Sigma receptors are membrane associated proteins found widely
distributed in the mammalian brain, peripheral neurons, and visceral organs.
These receptors were first identified by Martin et al., and have since been
classified into two types on the basis of pharmacology, sigma-1 and sigma-2
(Quirion et al. 1992). Both subtypes have high to moderate affinity for
antipsychotics, such as haloperidol, and guanidines. Sigma-1 receptors have a
higher affinity for (+)-benzomorphans, such as (+)-pentazocine, than sigma-2
receptors, whereas sigma-2 receptors have higher affinity for ibogaine and its
congeners. Thus far, only the sigma-1 receptor has been cloned, and this protein
is detected on the membranes of the endoplasmic reticulum and influences
calcium release from this organelle (Hayashi and Su 2001; Seth et al. 1998).
The sigma-1 receptor, with two putative transmembrane domains, bears
no resemblance to any other known mammalian protein. While the endogenous
ligand for sigma receptors has not been clearly identified, various candidates
have been suggested. N, N-dimethyltryptamine has been recently described as a
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nonsteriodal endogenous ligand for the sigma-1 receptor (Fontanilla et al. 2009),
perhaps explaining the significant anti-anxiolytic properties of sigma receptor
agonists. Neurosteroids like progesterone were also shown to bind sigma
receptors with high affinity, leading to the speculation that some of the
physiological actions of progesterone are mediated by sigma receptors (Su et al.
1990). Other neurosteroids, including pregnenolone and
dehydroepiandrosterone, have high affinity for sigma receptors. Given the
neuroprotective properties of neurosteroids and their abundance in the cortex,
these sigma ligands would be obvious candidates for the possible endogenous
neuroprotection by sigma receptors reported here.
Numerous in vivo studies have demonstrated a protective role for sigma
receptors following ischemia. Rats subjected to transient MCAO had reduced
infarct volume when various sigma ligands such as dimemorphan (Shen et al.
2008), (+)pentazosin (Takahashi et al. 1997), and 4-phenyl-1-(4-phenylbutyl)
piperidine (PPBP) (Takahashi et al. 1996) were administered during reperfusion.
Inhibition of various components of the early response to stroke such as NMDA
receptor activation, neuronal nitric oxide synthesis, and inducible nitric oxide
synthesis have been postulated to mediate this neuroprotection. Activation of
sigma receptors at 24 hours in the permanent MCAO model by DTG is also
neuroprotective (Ajmo et al. 2006), though at this timepoint it is likely that
modulation of the immune system plays a larger role in this effect.
The neuroprotective properties of sigma receptors in vitro have been
ascribed to their ability to stabilize intracellular calcium levels due to NMDA
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receptor activation and block anoxic depolarization. Subsequent studies
demonstrate that sigma receptor activation blocks ischemia induced calcium
increases by suppressing calcium influx through multiple pathways (Katnik et al.
2006). Recent work demonstrates that sigma receptor activation suppresses
acid sensing ion channel function (Herrera et al. 2008). This family of channels
induces calcium influx in the presence of high levels of extracellular protons
generated by glycolysis and excessive neurotransmission (Xiong et al. 2007).
Pharmacological inhibition of this ion channel is protective when administered
within 5hrs of MCAO (Xiong et al. 2008). It remains to be determined whether
the benefit seen in vivo; due to these effects at the levels of the neuron or due to
the effects of sigma receptor activation on immune system function, or both.
A role of sigma receptors in the immune system was first proposed by T.P.
Su et al. based on their observation that lymphoid tissues express sigma binding
sites (Su et al. 1988). Subsequent studies have shown that sigma receptor
activation can regulate the function of various cells of the immune system.
Selective sigma-1 receptor activation is associated with reduced leukocyte
invasiveness and decreased levels of inflammatory cytokines in vivo (Zhu et al.
2003). Sigma ligands such as (+) pentazocine, haloperidol, and DTG suppress
in vitro murine splenocyte natural killer activity and polyclonal immunoglobulin
production following mitogen stimulation (Carr et al. 1991). Systemic
administration of the sigma ligand, SR 31747A, inhibits the secretion of TNF-α
and IFNγ evoked by injection of LPS in rats (Bourrie et al. 2002). This sigma
ligand has also been shown to inhibit NO production in LPS-activated
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macrophages (Gannon et al. 2001). In the CNS, sigma-1 receptors are
expressed in microglia (Gekker et al. 2006), and our laboratory has shown that
sigma receptor activation is associated with decreased reactive gliosis following
stroke injury in rats (Ajmo et al. 2006). The immunosuppressive effects of
cocaine have been attributed to sigma receptor activation via heightened
expression of TGF-β (Gekker et al. 2006), an anti-inflammatory cytokine altered
following ischemia.

Determining the impact of DTG on the post ischemic inflammatory
response-the current project
While sigma ligands have been studied in the treatment of ischemia,
previous projects have focused on reperfusion injury, neuronal calcium
dysregulation, and/or anoxic depolarization. While these studies are useful for
understanding sigma receptor biology during early ischemia, they have very little
relevance to the clinical condition. The major caveat with attempting to intervene
in these pathological systems is that they typically occur at timepoints well before
patients are seen for treatment. A major finding in our lab, centers around the
ability of DTG to impart significant neuroprotection when therapy is administered
24 hours following permanent MCAO. The only other treatments which have
efficacy at such delayed timepoints such as minocycline and HUCBC have
immunomodulatory properties.
Microglia are the endogenous immune cells of the brain and are
intrinsically linked to induction, development, and maintenance of the post
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ischemic inflammatory response. The first set of experiments described here
were undertaken to test the following hypotheses: (1) sigma receptor
activation suppresses microglial activation in culture, and (2) suppression
of intracellular calcium is the process which sigma receptor activation
targets to suppress microglial activation.
Dissociated microglial cultures are a good model for elucidating
intracellular signaling cascades which occur during activation. The relevance of
this model to ischemic injury however is low. The organotypic slice culture model
has many advantages over dissociated cell culture. Principal among these is
that all cell types found in brain parenchyma are present and many of their
functional connections are maintained. When these cultures are subjected to
ischemic conditions, microglia are activated in conditions similar to those found in
vivo. Furthermore as sigma receptor activation modulates microglial and
peripheral leukocyte activation this model allows the exploration of the effect of
sigma receptor activation without the input of the peripheral immune system.
The second set of experiments presented here explores the following
hypotheses: (1) that ischemia results in robust neurodegeneration
resulting in microglial activation as measured by nitric oxide production,
and (2) sigma receptor mediated suppression of microglial activation
confers neuroprotection.
In vivo, peripheral immune cells infiltrate the infarct prior to the 24 hour
timepoint at which DTG is efficacious. Peripheral T-lymphocytes in particular are
involved in stroke induced neurodegeneration, likely through interactions with
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antigen presenting cells like macrophages/microglia residing in the infarct. One
source of T-lymphocytes which contributes to ischemic neurodegeneration is the
spleen. Sigma receptor activation can modulate T-cell antigen presenting cell
interaction by upregulating the production of anti-inflammatory cytokines IL10
and TGFβ in T-cells and microglia respectively decreasing peripheral
inflammation. Therefore, the third set of experiments presented here will
test the hypothesis that: (1) splenic peripheral immune cells infiltrate the
infarct following MCAO, and (2) DTG treatment reduces the prevelance of
these cells in the infarct
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Chapter 2
Sigma Receptors Suppress Multiple Aspects of Microglial Activation

Hall Aaron A., Herrera Yelenis, Ajmo Jr. Craig T., Cuevas Javier, Pennypacker
Keith R.

Abstract
During brain injury, microglia become activated and migrate to areas of
degenerating neurons. These microglia, release pro-inflammatory cytokines and
reactive oxygen species causing additional neuronal death. Microglia express
high levels of sigma receptors, however, the function of these receptors in
microglia and how they may affect the activation of these cells remain poorly
understood. Using primary rat microglial cultures, it was found that sigma
receptor activation suppresses the ability of microglia to rearrange their actin
cytoskeleton, migrate, and release cytokines in response to the activators
adenosine triphosphate (ATP), monocyte chemoattractant protein 1 (MCP-1),
and lipopolysaccharide (LPS). Next, the role of sigma receptors was explored in
the regulation of calcium signalling during microglial activation. Calcium
fluorometry experiments in vitro show that stimulation of sigma receptors
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suppressed both transient and sustained intracellular calcium elevations
associated with the microglial response to these activators. Further experiments
showed that sigma receptors suppress microglial activation by interfering with
increases in intracellular calcium. In addition, sigma receptor activation also
prevented membrane ruffling in a calcium-independent manner, indicating that
sigma receptors regulate the function of microglia via multiple mechanisms.

Introduction
A principal aspect of the central nervous system (CNS) immune response
to injury is the recruitment and activation of endogenous microglia. Microglia are
the resident macrophages of the brain, which are kept in a quiescent ramified
state under normal conditions. These cells respond to substances released by
damaged neurons or invading pathogens by migrating to the site of injury,
phagocytosing debris, and releasing pro-inflammatory mediators, such as
cytokines and reactive oxygen species (Streit et al. 2004). In several
pathological states of the CNS, this response contributes to the destruction of
compromised neurons enhancing neurodegeneration (Dheen et al. 2007; Rogove
et al. 2002; Streit et al. 2004). Current research suggests that the inflammatory
response after brain injury can be inhibited by sigma receptor activation (Ajmo et
al. 2006). These receptors are neuroprotective in several animal models of
stroke injury (Ajmo et al. 2006; Harukuni et al. 1998), and represent a putative
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target for neuroprotection at delayed time points (≤ 24 hrs) following stroke onset
(Ajmo et al. 2006).
Sigma receptors are membrane associated proteins found widely
distributed in the mammalian brain, peripheral neurons, and visceral organs. Two
subtypes of sigma receptors, sigma-1 and sigma-2, have been identified based
on their pharmacological profiles (Quirion et al. 1992). Thus far, only the sigma-1
receptor has been cloned (Seth et al. 1998), and this protein is detected on the
membranes of the endoplasmic reticulum and influences calcium release from
this organelle (Hayashi and Su 2001).
Sigma receptors were identified in the immune system using radioligand
binding studies in lymphoid tissues (Su et al. 1990). Selective sigma-1 receptor
activation is associated with reduced leukocyte invasiveness and decreased
levels of inflammatory cytokines in vivo (Zhu et al. 2003). Sigma ligands such as
(+) pentazocine, haloperidol, and 1,3-di-o-tolylguanidine (DTG) were found to
suppress murine splenocyte activity and polyclonal immunoglobulin production
following mitogen stimulation in vitro (Carr et al. 1991). Systemic administration
of the sigma ligand, SR 31747A, inhibits the secretion of tumor necrosis factor-α
(TNF-α) and interferon gamma (IFN-γ) evoked by injection of LPS in rats (Bourrie
et al. 2002). This sigma ligand has also been shown to inhibit nitric oxide (NO)
production in LPS-activated macrophages (Gannon et al. 2001). In the CNS,
sigma-1 receptors are expressed in microglia (Gekker et al. 2006), and our
laboratory has shown that sigma receptor activation is associated with decreased
reactive gliosis following stroke injury in rats (Ajmo et al. 2006).
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This study investigated sigma receptor modulation of microglial activation.
Specifically, experiments were done to characterize the effects of sigma receptor
activation on morphological, migratory, and inflammatory responses of microglia
and to determine the role of intracellular calcium concentration on the regulation
of these processes. It was found that sigma receptor activation suppressed the
morphological, migratory, and inflammatory aspects of microglial activation.
Further studies revealed that sigma receptor activation regulates these
processes by suppressing calcium increases. However, calcium-independent
regulation of microglia activation by sigma receptors was also noted, indicating
that sigma receptors regulate these cells by affecting various signaling pathways.

Materials and Methods

Primary Cultures of Microglia
Primary cultures of microglia were prepared from postnatal (2 day)
Sprague-Dawley rat pups using a protocol modified from Gottschall et al
(Gottschall et al. 1995). Briefly, pups were decapitated, cortices dissected out
and dissociated in Hank’s balanced salt solution containing 0.25% Trypsin and
2.21 mM ethylenediaminetetraacetic acid (EDTA) (Mediatech, Manassas, VA).
Isolated cortical cells were plated into poly-D-lysine (Sigma-Aldrich, St. Louis,
MO) treated tissue culture flasks. The mixed glial cultures for the preparation of
microglia were maintained in high glucose Dulbecco’s Modified Eagle Media
(DMEM, Invitrogen, Carlsbad, CA) supplemented with 10% horse serum, 2.5%
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fetal bovine serum, and an antibiotic/antimycotic cocktail containing 100 I.U.
penicillin, 100 μg/ml streptomycin, and 0.25 μg/ml amphotericin B. The mixed
glial cultures were incubated for 8-10 days at 37 o C. Microglia were then
dislodged by vigorous shaking, plated, and used for experiments the following
day.

Membrane Ruffling and Quantification
Microglia plated on poly-D-lysine treated glass coverslips were serum
starved for four hours in DMEM then stimulated for 5 or 10 minutes with ATP
(Sigma-Aldrich, St. Louis, MO) or 10 min with MCP-1 (Peprotech Inc., Norwood,
MA). Compounds to be tested were incubated with the microglia in DMEM for 10
minutes prior to chemoattractant exposure. In one series of experiments Ca2+free DMEM (Invitrogen) was used. Cytoskeletal changes were visualized using
phalloidin conjugated to AlexaFluor 488 (Invitrogen).
Multiple photomicrographs (n ≥ 4) of fields containing 1-8 cells were
acquired for controls (DMEM) and each test group. Morphology of the cells was
evaluated by an investigator blind to the nature of the treatment and a score was
given to each cell using the following criteria: “0” was given to cells which did not
display any signs of membrane ruffling and had multiple apparent filopodia; “1”
was given to cells which retained filopodia and lamellipodia, but which also had
regions on the cell membrane where ruffling was present; and “2” was given to
cells which had withdrawn all their filopodia and displayed a fully ruffled
phenotype. The scores in each group were then summed and divided by the
51

number of cells assayed in that group to yield that group’s degree of membrane
ruffling which was expressed in arbitrary units (A.U.). Means for each group
were compared and significant differences were determined via two-way ANOVA
with post-hoc Bonferroni tests.

Migration Assay
Modified Boyden chambers were used as previously described (McCord et
al. 2005). Briefly, 5x105 freshly isolated microglia were applied to the top portion
of a Boyden chamber assembled with an 8 μm pore polycarbonate membrane.
Media (DMEM) containing vehicle or chemoattractant (ATP or MCP-1) with or
without compounds to be tested was added to the bottom of the chamber, and
the cells incubated for four hours at 37oC. The membranes were removed and
microglia adhering to the top of the membrane were scraped off. The membrane
was oriented on a slide such that the cells that migrated to the bottom of the
membrane were facing up. Vectashield Hardset mounting media (Vector Labs,
Burlingame Ca) containing 4'-6-diamidino-2-phenylindole (DAPI) was applied to
the membrane and a coverslip affixed to the slide. DAPI positive cells were
illuminated at 359 nm and visualized at 461 nm using a Zeiss Axioskop 2
outfitted with a 20X objective. A minimum of 5 random fields of cells were
counted and averaged per membrane, and the results of at least three
experiments were averaged.
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ELISA assay
Plates (96 well) were coated with 2 ng/ml capture antibody (tumor necrosis
factor-α, MAB510 anti-rat antibody; interleukin-10, MAB519 anti-rat antibody;
R&D Systems, Inc., Minneapolis, MN) overnight at 4oC. The plates were washed
with Tris buffered saline (TBST) consisting of: 20 mM Tris pH 7.5, 150 mM NaCl,
and 0.05% Tween 20. The plates were then blocked with 1% bovine serum
albumin (BSA) in TBST for 1 hour. A standard curve was prepared using
recombinant protein standards. The standards as well as the unknowns were
incubated for 1hr at room temperature and then washed with TBST. Biotinylated
detection antibody (tumor necrosis factor-α, #BAF510 biotinylated anti-rat
antibody; interleukin-10, #BAF519 biotinylated anti-rat IL10 antibody; R&D
Systems, Inc., Minneapolis, MN) was added to each well at 100 ng/ml and
incubated for 2 hrs at room temperature. After incubation, the plates were
washed three times with phosphate buffered saline (PBS) containing (in mM): 3.2
Na2HPO4, 0.5 KH2PO4, 1.3 KCl, 135 NaCl (pH 7.4). Streptavidin conjugated to
horseradish peroxidase (streptavidin-HRP) was added to each well followed by
20 min incubation at room temperature. After washing, 100 μl of 3,3’,5,5’tetramethyl-benzidine (TMB) (Sigma-Aldrich, St. Louis, MO) was added and
incubated for 5 minutes in the dark. Finally, 50 μl of 1 M H2SO4 stop solution
was added to each well and optical density was measured using a microplate
reader set at 450 nm.
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Griess reaction
Supernatants from treated primary rat microglia cultures were collected,
and clarified by centrifugation. Nitric oxide levels in the supernatant were
determined using the Griess Reagent Kit (Invitrogen) according to the
manufacturer’s protocol.

Calcium Imaging
Intracellular calcium ([Ca2+]i) was measured using the ratiometric Ca2+
sensitive dye, fura-2 as previously described (Katnik et al. 2006). Microglia,
plated on coverslips, were incubated for 1 hour at 37oC in DMEM (Mediatech,
Manassas, VA) containing 5 μM fura-2, acetoxymethylester (fura-2 AM;
Invitrogen) and 0.1 % dimethyl sulfoxide (DMSO). The coverslips were washed
in physiological saline solution (PSS) consisting of (in mM): 140 NaCl, 5.4 KCl,
1.3 CaCl2, 1.0 MgCl2, 20 glucose, and 25 4-(2-hydroxyethyl)-1piperazineethanesulfonic acid (HEPES) (pH adjusted to 7.4 with NaOH) prior to
the experiments being carried out. A DG-4 high speed wavelength switcher
(Sutter Instruments Co., Novato, CA) was used to apply excitation light of
alternating wavelength (340/380nm). Fluorescent emission was captured using a
Sensicam digital CCD camera (Cooke Corporation, Auburn Hills, MI) and
recorded with Slidebook 3.0 software (Intelligent Imaging Innovations, Denver,
CO). Changes in [Ca2+]i were calculated using the Slidebook 3 software.
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DAF Imaging
Nitric oxide concentration was measured using the NO sensitive dye, 4amino-5-methylamino-2',7'-difluorofluorescein (DAF-FM). Microglia plated on
coverslips were incubated for 1 hour at 37oC in DMEM (Mediatech) containing
5μM DAF-FM (Invitrogen) and 0.1 % DMSO. The coverslips were washed in
PSS prior to NO measurements. DAF-FM loaded cells were illuminated at 488
nm and visualized at 510 nm, using the same instrumentation described for
calcium imaging experiments. Background fluorescence was determined by
measuring fluorescent intensities in areas between cells and was subtracted from
the raw intensity values. Fluorescent intensity was expressed as arbitrary units.

Data Analysis
Analysis of measured intracellular [Ca2+] responses was conducted using
Clampfit 9 (Molecular Devices, Union City, CA). Statistical analysis was
conducted using SigmaPlot 9 and SigmaStat 3 software (Systat Software, Inc.,
San Jose, CA). Two-way ANOVA procedures with appropriate post-hoc tests
were used to analyze data from the calcium imaging and migration experiments,
while a three-way ANOVA procedure with post-hoc Tukey’s test was used to
analyze data from the NO imaging experiments.
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Reagents
The sigma ligands DTG and metaphit were obtained from Tocris
Bioscience (Ellisville, MO). The microglial activator MCP-1 was purchased from
Peprotech Inc., (Norwood, MA), ATP and LPS from Sigma-Aldrich (St. Louis,
MO), thapsigargin from Alomone Labs (Jerusalem, Israel), and ionomycin from
Calbiochem (San Diego, CA). All other reagents were purchased from SigmaAldrich and were of analytical grade or higher.

Results

Sigma receptor activation suppresses changes in microglia morphology in
response to chemoattractant stimulation.
ATP released from degenerating neurons activate microglia during brain
injury (Davalos et al. 2005). ATP binds purinergic receptors on microglia and
causes microglia to change shape and migrate to the site of injury (Honda et al.
2001). To study these phenomena, microglia were treated with ATP and labeled
using phalloidin, which binds to the actin cytoskeleton. Unstimulated microglia
exhibited discrete, actin rich filopodia (Figure 1A and 1D). Upon stimulation with
ATP (100 µM), for either 5 min (Figure 1B) or 10 min (Figure 1E) microglia
retracted their filopodia and aggregated actin along the leading edge of the cell
membrane in a manner consistent with membrane ruffling. Administration of the
sigma receptor agonist DTG (100 µM) 10 min prior to and during ATP exposure
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decreased the aggregation of actin in the leading edge and promoted the
retention of filopodia (Figure 1C and 1F). DTG treatment alone resulted in cells
which were morphologically indistinguishable from control (data not shown).
Since ATP-induced retraction of filopodia is an extracellular Ca2+-independent
process, experiments were also carried out in nominal extracellular Ca2+. In the
absence of extracellular Ca2+, microglia exhibited normal morphology, and
filopodia were readily observed (Figure 1G). Upon application of ATP (5 min),
filopodia were retracted and membrane ruffling occurred (Figure 1H), and this
membrane ruffling was still inhibited by the addition of DTG (Figure 1I).
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Figure 1. Sigma receptor activation suppresses changes in microglia
morphology in response to chemoattractant stimulation.
Photomicrographs of primary rat microglia cultures exposed to vehicle (0.1%
DMSO in DMEM) (A, D, G), 100 μM ATP for 5 min (B, H) and 10 min (E), or 100
μM ATP for 5 min (C, I) and 10 min (F) in the presence of 100 μM DTG.
Microglia in A-F were treated in normal DMEM, whereas microglia in G-I were
treated in Ca2+-free DMEM. All insets represent magnified image (2.7x). Scale
bar = 2 μm.
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Sigma receptor activation significantly decreases membrane ruffling
induced by ATP.
The changes in membrane structure were quantified to determine if
activation of sigma receptors altered the morphological response to ATP. ATP
treatment significantly increased the degree of membrane ruffling relative to the
DMEM control (Figure 2). Furthermore, while in the control group no cells were
found to show complete membrane ruffling (n = 63), 62% of cells in the ATP
treatment group showed this phenotype (n = 53). DTG treatment alone had no
effect on membrane morphology, with 11 of the 12 cells examined showing no
evidence of membrane ruffling. However DTG pretreatment reduced the
response to ATP, as evident by the significant reduction in the degree of
membrane ruffling induced by the purine (Figure 2). The percentage of cells
which exhibited membrane ruffling decreased to 11% when DTG was co-applied
(n = 44).

59

Figure 2. Sigma receptor activation significantly decreases membrane
ruffling in microglia stimulated with ATP.
Degree of membrane ruffling assessed as described in the methods section.
Microglia were preincubated with vehicle, or DTG (100 μM DTG) for 5 minutes
then stimulated with DMEM or ATP (100 μM). Bars represent means ± SEM.
Asterisks indicate significant differences between DMEM and ATP within Control
(no DTG, p < 0.001) and DTG groups (p < 0.001). Pound symbol indicates
significant difference between Control and DTG within the ATP group (p < 0.001).
Significance was determined via two-way ANOVA with post-hoc Tukey’s Test.
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The microglial migratory response to chemoattractant application is
suppressed by sigma receptor activation.
A modified Boyden chamber was used to measure the chemotaxis of
freshly isolated microglia in response to ATP, with and without DTG present.
ATP (100 µM) promoted a ten-fold increase in the number of microglia that
migrated across the membrane relative to control (Figure 3A). This increase in
migration was statistically significant (p < 0.001) and similar to that previously
reported (Honda et al. 2001). DTG (300 μM) alone had no effect on microglial
migration (p = 0.47), but co-application of DTG with ATP significantly (p < 0.0001,
n = 3) depressed the ATP-evoked migration of microglia (Figure 3A) by 72.68 ±
3.55% relative to control (ATP and no DTG). In the presence of DTG, ATP failed
to evoke a statistically significant increase in migration above that observed when
DMEM was applied (p = 0.076).
The chemokine MCP-1, which binds the CCR2 receptor (Ogilvie et al.
2004), was also tested to determine whether sigma receptor mediated inhibition
of migration was limited to the effects elicited by purinergic receptors. Application
of MCP-1 (10 nM) caused a five-fold increase in the number of microglia that
migrated through the membrane compared to control (Figure 3B). This increase
in migration was less than that observed with ATP, but consistent with the 3- to
4-fold increase in macrophage and microglial migration reported for this
concentration of MCP-1 (Dzenko et al. 2001; Peterson et al. 1997). Co-treatment
with 300µM DTG significantly depressed MCP-1-induced microglial migration
relative to the control group (p < 0.001, n=4). Furthermore, there was no
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statistical significance between MCP-1 and DMEM-induced migration in the
presence of DTG (p = 0.56, Figure 3B).

Figure 3. The microglial migratory response to chemoattractant application
is suppressed by sigma receptor activation.
Microglial migration was assayed using a Boyden chamber fitted with a
polycarbonate membrane containing 8μm pores. Microglia (500,000 cells) were
placed in the upper chamber and control media, 100 μM ATP (A) or 10 nM MCP1 (B) were added in the absence and presence of 300 μM DTG to the bottom
chamber. Microglia were allowed to migrate for 4 hrs at 37 °C, then stained with
DAPI and counted. Asterisks indicate a significant difference between ATP (A; p
< 0.001, n = 6) and MCP-1 (B; p < 0.01, n = 4) from DMEM within the Control
group (no DTG). Pound symbols indicate significant difference between Control
and DTG within the ATP (A; p < 0.001) and MCP-1 (B; p < 0. 01) groups,
respectively. In both cases significance was determined by two-way ANOVA
followed by post-hoc Bonferroni tests.
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The microglial inflammatory response is suppressed by sigma receptor
activation.
To ascertain whether sigma receptors modulated the pro-inflammatory
response of microglia, cytokine, and NO production evoked by LPS were
examined after pretreatment with DTG. LPS activates microglia and causes
robust increases in cytokine production (Hoffmann et al. 2003). Microglial
cultures were preincubated with varying concentrations of DTG (50-1000μM) for
30 minutes and the cells were then activated with LPS (1μg/ml). TNFα and IL10
levels in the supernatant were measured using ELISA and NO levels were
quantified with the Greiss reaction. DTG suppressed both cytokine and NO
production in a concentration dependent manner (Figure 4). Fits of the data
determined IC50 values of 338.9, 109.6, and 166.0µM for DTG inhibition of TNFα,
IL10, and NO release, respectively (n = 4 for all groups tested).
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Figure 4. The microglial inflammatory response is suppressed by sigma
receptor activation.
Primary microglial cultures were incubated with LPS (1 μg/ml) for 24 hrs and in
Levels in the supernatant of TNFα and IL10 were measured by ELISA, while NO
was measured by the Greiss reaction. Data points represent mean ± SEM for
TNFα, IL10, and NO levels as a function of DTG concentration (n=4 for all
groups). Lines indicate best fits to the data using a Langmuir-Hill equation and
yielded IC50 values of 338.9, 109.6, and 166.0µM with Hill coefficients of 1.90,
1.94, and 1.4 for TNFα, IL10, and NO release, respectively.
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Transient intracellular calcium signaling is suppressed by sigma receptor
activation.
Changes in intracellular calcium are a critical component of the signaling
cascade triggering the immune response of microglia. Given that sigma receptors
regulate intracellular calcium concentrations ([Ca2+]i) in neurons (Katnik et al.
2006), it seemed prudent to examine the effects of sigma receptor activation on
changes in [Ca2+]i following microglia stimulation. Focal application of 300 µM
ATP (10 sec) onto microglia produced intracellular calcium increases of 140.4 ±
16.2 nM in ~90% of cells tested (Figure 5A). Following pretreatment (10 min)
with 100 µM DTG, the ATP-elicited increases in [Ca2+]i were reduced by 82 ±
16.4% (n=39), which was statistically significant (p < 0.001, Figure 5C). To
confirm that DTG was acting via sigma receptors, cells were preincubated with
the irreversible sigma receptor antagonist metaphit. Pretreatment with metaphit
(50 μM, 1 hr, room temperature) abolished the inhibitory effects of DTG on ATPinduced [Ca2+]i increases (Figure 5B), such that no statistically significant
difference (p = 0.52) existed between the ATP-induced [Ca2+]i responses
observed in the absence (ATP + Met) and presence of DTG (ATP + DTG + Met)
(Figure 5C).
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Figure 5. Transient intracellular calcium signaling evoked by ATP was
suppressed by sigma receptor activation.
Representative traces of [Ca2+]i as a function of time recorded during ATP (300
µM) stimulation in the absence (Control) and presence of DTG (100 μM), without
(A) or with (B) Metaphit (50 μM, 1 hr, room temperature). C, Mean change in
peak [Ca2+]i (± SEM) measured in the above treatment groups. Asterisk denotes
significant difference (p < 0.05, n = 25), as measured by one-way ANOVA with
post-hoc Dunn’s test using ATP as control.
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Basal intracellular calcium increases are suppressed by sigma receptor
activation.
To determine whether DTG could inhibit the sustained increase in [Ca2+]i
associated with the LPS-induced inflammatory response (Boddeke et al. 1999;
Hoffmann et al. 2003), microglia were treated with LPS for 24 hours and then the
basal intracellular calcium was measured. Treatment with LPS evoked a 46.1 ±
11.0% increase in [Ca2+]i relative to control cells and this increase was
statistically significant (p < 0.05, n = 31 Figure 6). In contrast, in cells pretreated
with 300 µM DTG, LPS failed to evoke increases in [Ca2+]i (Figure 6). This
inhibition of basal [Ca2+]i by DTG was statistically different from LPS treatment
alone (p < 0.05, n = 31). These results are consistent with the hypothesis that
sigma receptors inhibit the inflammatory response elicited by LPS via the
inhibition of LPS-induced increases in intracellular calcium.
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Figure 6. Basal intracellular calcium increases are suppressed by sigma
receptor activation.
Microglia, plated on poly-D-lysine coverslips, were stimulated for 24 hours with
LPS (1μg/ml) in the absence (Vehicle) and presence of 300 μM DTG. Mean
basal calcium levels (± SEM) were measured using fura-2 calcium imaging.
Values represent measurements from three pooled experiments each having a
minimum of 30 cells per group. Asterisks denote statistical difference (p < 0.05,
n = 31) between Media and LPS treatment groups within the Vehicle group, and
pound symbols denote significant difference between Vehicle and DTG within the
LPS treatment group (p < 0.05, n=31). Statistical difference was determined
using a two-way ANOVA with post-hoc Bonferroni test.
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Increases in intracellular calcium are sufficient to induce membrane
ruffling in microglia.
The calcium ionophore ionomycin was used to increase intracellular
calcium in microglia via a pathway distinct from the sigma receptor-sensitive
influx pathways activated in response to ATP, MCP-1 and LPS. Ionomycin
treatment alone altered the morphology of microglia by promoting retraction of
filopodia and inducing membrane ruffling when compared to control (Figure 7A
and 7B). Unlike the results obtained when ATP was used to stimulate actin
rearrangement, DTG was unable to inhibit ionomycin-induced membrane ruffling
(Figure 7C). Quantification of the results obtained with ionomycin and DTG
treatment is summarized in Figure 7D. Ionomycin evoked a statistically
significant increase in the degree of membrane ruffling both in the absence and
presence of DTG preincubation, and no significant interaction was noted
between sigma receptor stimulation and the response to the ionophore. These
data show that increasing [Ca2+]i is sufficient to promote such changes in
microglial morphology. Moreover, the inability of DTG to decrease these
ionomycin-evoked changes to the membrane suggest that sigma receptors are
acting at the level of [Ca2+]i and not at downstream targets of this molecule.
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Figure 7. Increases in intracellular calcium induce membrane ruffling in
microglia.
Micrographs of phalloidin stained microglia treated with vehicle (DMSO, A), 1μM
ionomycin for 5 minutes (B), and 1μM ionomycin + 100μM DTG. D, Bar graph of
degree of membrane ruffling determined for the indicated conditions. Bars
represent means ± SEM. Asterisks indicate a significant difference between
DMEM and Ionomycin treatment groups (p < 0.001). Significance was
determined via two-way ANOVA with post-hoc Tukey Test. All insets represent
magnified image (2.7x). Scale bar = 2 μm.
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Microglial migration is a calcium dependent process which is not restored
by ionomycin treatment.
We next investigated whether ionomycin could overcome the blockade of
microglial chemotaxis observed following sigma receptor activation. The
membrane ruffling evoked by ionomycin was not associated with an increase in
chemotaxis, and the number of migrating cells observed in response to
ionomycin treatment was similar to that observed with vehicle alone (Figure 8A).
Chemotaxis was observed as before in response to ATP, and it was significantly
inhibited by co-administration of DTG. However, microglial migration in response
to ATP was disrupted by ionomycin treatment alone (Figure 8A). In contrast to
the observed effects on the microglial morphological response, the addition of
ionomycin failed to promote microglial chemotaxis in the presence of ATP and
DTG, instead significantly further decreasing migration relative to that observed
in the ATP+DTG group.

Microglial migration is independent of calcium release from internal stores
but requires calcium influx.
To determine the source of increased [Ca2+]i necessary for microglial
migration, calcium release from intracellular stores and influx from the
extracellular media were selectively blocked prior to ATP-stimulation. The
sarcoplasmic-endoplasmic calcium ATPase inhibitor thapsigargin was used to
deplete calcium from the ER by blocking reuptake. Pretreatment with 10 μM
thapsigargin alone, failed to suppress the migratory response to ATP (Figure 8B).
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In thapsigargin treated samples, 100 μM ATP stimulated cell migration averaged
747.0 ± 190 cells per field compared to 683 ± 187 cells per field in control
samples (p = 0.67, n = 4) . The pan-selective calcium channel blocker La3+ was
employed to block calcium channel mediated influx through the plasma
membrane. Lanthanum alone did not promote a significant change in migration
when compared to control (p = 0.4897, n = 5). However, co-application of 50 μM
La3+ with 100 μM ATP significantly suppressed microglial migration from 2069 ±
121 cells per field (ATP alone) to 1636 ± 124 cells per field (ATP + La3+) (Figure
8C, p = 0.022, n = 5). Figure 8D summarizes these results, showing that under
control conditions ATP induces a 320 ± 67 % increase in cell migration which is
reduced to 183 ± 32% in the presence of 50 μM La3+. Thus, inhibition of Ca2+
influx to the cell, such as that produced by sigma receptor activation, can prevent
microglia chemotaxis.
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Figure 8. Microglial migration is independent of calcium release from
internal stores but requires La3+-sensitive calcium influx.
A, Microglial chemotaxis in response to ATP (100μM) in the absence and
presence of DTG (300μM) and DTG with ionomycin ( μM). Data were analyzed
via two-way ANOVA with post-hoc Tukey test. Asterisk indicates a statistical
difference from respective controls (p <0.001 for all), pound symbol indicates a
statistical difference from ATP alone (p <0.001 for all), and dagger indicates
statistical significance from ATP+DTG (p <0.05 for all). B, Microglia migration
induced by 300μM ATP without and with pretreatment of the cells with 10μM
thapsigargin for 30 min (37°C) (Thapsigargin). Asterisk indicates a statistical
difference from control (p <0.05). Bar represent means ± SEM, n = 3. C,
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Microglia migration evoked by 300μM ATP in the absence (Control) and
presence of 50μM La3+. Asterisk indicates a statistical difference from Control (p
< 0.001), pound symbol indicates a statistical difference from ATP alone (p <
0.01). Bar represent means ± SEM, n = 3. Statistical significance was determined
by two-way ANOVA followed by post-hoc Bonferroni multiple comparison tests.
D, Relative ATP induced migration in the absence (Control) and presence of
50μM La3+. Asterisk denotes statistical difference (p < 0.05 by student’s T test).

Calcium influx restores nitric oxide production following sigma receptor
activation in LPS stimulated microglia cells.
Increases in basal [Ca2+]i are integral to NO production in mouse microglia
(Hoffmann et al. 2003). Experiments were conducted to determine if ionomycin
facilitated Ca2+ influx would overcome the inhibitory effects of DTG on LPSinduced NO production. Primary microglia were preincubated (30 min) with
vehicle (0.1% DMSO in DMEM), DTG (300 µM), ionomycin (1 µM), or ionomycin
+ DTG in the presence and absence of LPS (1 µg/ml) for 24 hours. Nitric oxide
levels were measured using the intracellular NO indicator DAF-FM (Figure 9).
LPS stimulation alone increased NO levels 138.7 ± 10.87% compared to vehicle
(p < 0.001, n = 455). Co-application of DTG with LPS resulted in a statistically
significant suppression of NO levels (p < 0.001, n = 461), which were 22.2 ±
6.36% higher than that of the DTG control group. Application of LPS in the
presence of ionomycin produced an increase in NO similar to that observed
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when LPS was administered alone, such that NO levels were 129.9 ± 10.36%
greater than that of the ionomycin control group (p < 0.001, n = 446). In contrast
to the results observed for ATP-induced migration, addition of ionomycin to the
LPS + DTG group was able to overcome the inhibitory effects of sigma receptor
activation. When ionomycin was co-applied with LPS and DTG
(LPS+DTG+Iono) intracellular NO levels were increased by 86.1 ± 8.43% from
DTG+Iono control (p < 0.001, n = 418). These values were significantly greater
than those observed for the LPS + DTG group (p < 0.001, n = 418), and similar to
those elicited by the LPS + Iono group (p = 0.562, n = 446).
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Figure 9. Calcium influx restores nitric oxide production following sigma
receptor activation in LPS stimulated microglia.
Relative levels of NO produced by microglia under control condition (DMEM), in
the presence of 300µM DTG (DTG), and following application of 1μM ionomycin
alone (Iono) and with 300µM DTG (Iono + DTG). Microglia were also treated for
24 hrs with LPS (1μg/ml) alone (LPS), LPS and 300μM DTG (LPS+DTG), LPS
and 1μM ionomycin, and with a combination of the three compounds
(LPS+DTG+IONO). Bars represent mean fluorescent intensities from DAF-FM
loaded cells. Asterisk indicates statistical difference from DMEM treated cells,
pound symbol denotes statistical significance from LPS treated cells, and dagger
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indicates significance from LPS+DTG treated cells. In all cases p < 0.001, as
determined by three-way ANOVA with post-hoc Tukey test (n ≥ 400 cells for all
samples).

Discussion
The salient finding of this study is that sigma receptor activation can
suppress multiple aspects of microglial activation, including the morphological,
migratory and inflammatory responses to several known microglial activators.
The results of this study provide insight into the role of sigma receptors in the
regulation of immune system function. Sigma receptor activation can inhibit
membrane ruffling and migration of microglia, both of which are novel findings to
the best of our knowledge. As these processes are critical to the microglial
response to injury, these findings reveals a novel aspect of the modulation of
microglial activation by sigma receptors.
Resting microglia exhibit a ramified morphology in vivo characterized by
fine processes expressing chemosensitive receptors (Glenn et al. 1992).
Studies using GFP-labeled microglia in vivo demonstrated that these processes
are highly motile and quickly move towards ATP released by injured neurons
(Davalos et al. 2005). Upon further activation in vivo, these processes are
withdrawn and the microglia take on an amoeboid phenotype which is associated
with an inflammatory state (Kreutzberg 1996; Lyons et al. 2000). In vitro,
membrane ruffling decribes the cytoskeletal re-arrangements critical for the
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movements of microglial filopodia. Our results demonstrate that sigma receptor
activation blocks the formation of membrane ruffles in response to ATP
application. Metabotropic P2Y12 receptors, which evoke increases in [Ca2+]i in
microglia (Ohsawa et al. 2007), are critical to the induction of membrane ruffling
by ATP exposure (Honda et al. 2001). ATP also elicits a transient increase in
intracellular calcium via the activation of ionotropic P2X4 receptors expressed in
microglia. Intracellular calcium is an important co-factor in the process of
membrane ruffling, since either depression of intracellular Ca2+ with BAPTA or
deletion of the Ca2+-binding domain of Iba1, which is involved in ATP-induced
membrane ruffling in microglia (Kanazawa et al. 2002; Ohsawa et al. 2000),
inhibits agonist-elicited actin rearrangement in these cells (Ohsawa et al., 2000).
Elevations in intracellular calcium have also been implicated in macrophagecolony stimulating factor (M-CSF)-evoked membrane ruffling in microglia
(Ohsawa et al., 2000). Our studies show that increasing [Ca2+]i in microglia with
ionomycin treatment is sufficient to trigger membrane ruffling. Similarly, in rat
microglia/astrocyte co-cultures, the calcium ionophore calcimycine/A23187
evoked a loss of ramifications in microglia (Kalla et al. 2003). Sigma receptor
activation suppressed both the ATP mediated calcium transient and membrane
ruffling which suggests that the calcium increase is linked to membrane ruffling.
Sigma receptor activation was unable to inhibit the ionomycin-induced membrane
ruffling, indicating that sigma receptors are acting upstream of the calcium
elevation in this pathway.
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A second pathway which is [Ca2+]i-independent is able to induce
membrane ruffling in microglia. Previous studies have shown that purinergic
receptor mediated increases in intracellular calcium are necessary for migration
but not membrane ruffling in these cells (Honda et al. 2001; Ohsawa et al. 2007).
Sigma receptor activation depressed membrane ruffling in the absence of
extracellular Ca2+ and in conditions under which the Ca2+-independent
membrane ruffling induced by ATP is observed (Honda et al. 2001). Thus, sigma
receptor activation is able to disrupt membrane ruffling both by preventing [Ca2+]i
increases which may stimulate membrane ruffling and by blocking the Ca2+independent pathway.
While both membrane ruffling and migration in response to ATP are
dependent on P2Y12 receptor activation and intracellular calcium signaling,
migration must also incorporate chemoattractant sensing and directionality. In
our migration studies we saw robust migration in response to ATP and MCP-1,
both of which induce migration through a pertussis toxin sensitive Gi/o-protein
(Dzenko et al. 2001; Honda et al. 2001; Sozzani et al. 1994). Migration induced
by both chemoattractants was inhibited by sigma receptor activation, suggesting
that sigma receptors inhibit migration either by direct interaction with the Gi/oprotein or by interfering with downstream calcium signaling. Interestingly, unlike
membrane ruffling, increasing intracellular calcium levels with ionomycin failed to
restore microglial migration in the presence of sigma receptors. In fact, inclusion
of ionomycin effectively suppressed ATP induced migration. This effect may be
due to ionomycin-induced decreases in purinergic receptor signaling, which has
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been reported (Hoffmann et al. 2003). Alternatively, the homogeneous
elevations in [Ca2+]i produced by ionomycin treatment may saturate and disrupt
any directional effects produced by the purinergic signaling. Similarly, the Ca2+
ionophore, A23187, disrupts microglial migration in response to complement 5a
(Nolte et al. 1996). In contrast, depletion of intracellular calcium stores with
thapsigargin had no effect on migration, whereas the calcium channel inhibitor
lanthanum partially suppressed microglial migration in response to ATP. This
latter finding is consistent with ionotropic P2X4 receptor signaling being essential
to ATP induced microglial activation, which has been reported (Ohsawa et al.
2007). Given that sigma receptor activation decreased the calcium signaling
known to be essential for microglial migration, this is the likely mechanism by
which sigma receptor activation suppresses movement of the cells.
Another crucial component of microglial function is the induction of the
inflammatory response. Activation of sigma receptors in the peripheral immune
system potently suppresses the inflammatory response to a variety of stimuli
(Bourrie et al. 2002). It was proposed that these anti-inflammatory effects were
mediated by sigma receptor-induced interleukin-10 (IL10) production (Zhu et al.
2003). However, studies on sigma receptor-mediated immunosuppression in
RAW 264.7 macrophages suggested that IL10 is not always involved in these
responses (Gannon et al. 2001). This latter observation is consistent with our
finding that IL10 production in response to LPS treatment was decreased with
similar kinetics to reductions of TNF-α and NO production. This observation
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implies that sigma receptor activation affects signaling upstream of protein
synthesis-dependent processes in the inflammatory response.
Sustained increases in basal intracellular calcium levels are integral to the
induction of the inflammatory response (Hoffmann et al. 2003). Sigma receptor
activation reduces the capacity of microglia to generate this sustained increase in
calcium in response to LPS. This is associated with a decreased release of
cytokines and NO. Reintroduction of calcium with ionomycin overcame the
sigma receptor activation induced blockade of NO production.
Our results showing that activation of sigma receptors suppresses ATPinduced [Ca2+]i in microglia suggest that sigma receptors are inhibiting P2X
receptors in these cells, since these channels account for most of the increase in
[Ca2+]i observed in our experiments (data not shown). Previous studies,
including works from our laboratory, have shown that sigma receptors couple to
both voltage-gated and ligand-gated ion channels (Aydar et al. 2002; Herrera
2007; Zhang and Cuevas 2002; Zhang and Cuevas 2005). Thus, this
observation is consistent with the hypothesis that sigma receptors couple to a
diverse group of ion channels. While the regulation of these plasma membrane
ion channels will affect [Ca2+]i, sigma receptors also affect other proteins which
influence [Ca2+]i, including the IP3 receptor of the endoplasmic reticulum and the
BiP chaperone found in the mitochondrion-associated ER membrane (Hayashi
and Su 2001; Hayashi and Su 2007). However, the fact that sigma receptors
affect membrane ruffling in the absence of Ca2+ signaling indicates that the
influence of sigma receptors on microglial function is not limited to the regulation
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of Ca2+ signaling alone. Thus, the mechanisms by which sigma receptors
regulate the activity of microglia remain to be fully elucidated.
Activated microglia are associated with neurodegenerative disease
progression (Streit et al. 2004), and the presence of activated microglia is linked
to increased neuronal damage. In contrast, ablation of microglia is also
associated with increased damage (Lalancette-Hebert et al. 2007), which shows
that microglia play a complex part in the etiology of neurodegenerative disease.
Our findings support and expand upon the theory that sigma receptors have
potent immunoregulatory properties (Bourrie et al. 1995; Bourrie et al. 2002).
Prior to our work, the relationship between sigma receptors and microglia had
only been studied in an in vitro HIV-1 infection model (Gekker et al. 2006). Our
studies shed light on the mechanism by which sigma receptors modulate the
function of microglia in response to brain injury.
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Chapter 3
Delayed treatments for Stroke Differentially affect Neuronal Death in
Organotypic Slice Cultures Subjected to Oxygen Glucose Deprivation

A.A.Hall, C.C. Leonardo, L.A.Collier, D.D. Rowe, A.E.Willing, and
K.R.Pennypacker

Abstract
Stroke induced brain injury is the third leading cause of death and disability in the
United States. A major limitation of current stroke therapies is the need to treat
candidate patients within three hours of stroke onset. Human umbilical cord
blood cell (HUCBC) and the sigma receptor agonist 1,3, di-o-tolylguanidine
(DTG) administration both caused significant reductions in brain damage in the
rat middle cerebral artery occlusion model of stroke when administered at
delayed timepoints. In vivo, these treatments suppress the infiltration of
peripheral lymphocytes into the brain in addition to decreasing
neurodegeneration. It appears that neuroprotection afforded by both treatments
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is a product of their actions on the peripheral immune system as well as a direct
effect on the ischemic brain tissue. An ex vivo organotypic slice culture (OTC)
model to was utilized to characterize the efficacy of these treatments in mitigating
neurodegeneration in ischemic brain tissue in the absence of the peripheral
immune system. Slice cultures subjected to oxygen glucose deprivation (OGD)
had significantly elevated levels of degenerating neurons and microglial nitric
oxide production when compared to their normoxia counterparts. HUCBC but
not DTG treatment reduced the number of degenerating neurons and the
production of microglia derived nitric oxide in slice cultures subjected to OGD
back to levels seen in the normoxia controls. These data show that HUCBC
treatment can mediate direct neuroprotection and suppress innate inflammation
in ischemic brain tissue in the absence of the peripheral immune system,
whereas DTG requires peripheral effects to mediate neuroprotection. These
experiments yield insight into the mechanisms by which neuroprotective
treatments function at delayed timepoints following stroke.

Introduction
Currently the only FDA approved treatment for ischemic stroke is
recombinant tissue plasminogen activator (Alteplase) (Marler and Goldstein
2003). This treatment works by dissolving the blood clot occluding the offending
blood vessel. Unfortunately its use is restricted to a short, 3-6 hour, time window.
Beyond this time, apoptotic and inflammatory processes greatly diminish the
therapeutic benefits of current treatments. Furthermore this treatment increases
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the risk for bleeding and only provides a modest (13%) benefit in mortality and
morbidity to patients who are candidates for this treatment (Marler and Goldstein
2003).
Attempts to develop therapies to increase neurosurvival have not been
successful clinically thus far. The vast majority of trials to date have focused on
reducing the buildup of intracellular calcium, neuronal firing, and free radicals.
These therapies were developed in order to combat a phenomenon called
excitotoxicity which is thought to damage neurons (Dirnagl et al. 1999).
Neuronal damage due to excitotoxicity is caused by the release of
glutamate which causes overactivation of ionotropic AMPA and NMDA
glutaminergic receptors on ischemic neurons. The increased AMPA and NMDA
receptor activation causes sodium and calcium to enter the cell where it can
depolarize neurons and increase excitability and firing. Under ischemic
conditions this depolarization results in further metabolic demand and can drop
ATP levels below those needed to maintain ionic homeostasis. The resulting
anoxic depolarization causes a further calcium influx which activates proapoptotic
signaling cascades, causing free radical buildup, and neuronal death. While
these therapies have been successful in vitro, their efficacy in animal studies was
restricted to early timepoints (<3 hrs). Furthermore reducing excitability by
blocking NMDA receptors or calcium channels was associated with intolerable
side effects such as hallucinations and dizziness (NMDA) (Davis et al. 2000) and
reductions in blood pressure (calcium channel blockers) (Horn et al. 2001).
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Two experimental treatments which have shown a great deal of promise in
experimental rat models of focal ischemia are human umbilical cord blood cells
(HUCBC) (Vendrame et al. 2004) and 1,3-di-o-tolylguanidine (DTG) (Ajmo Jr et
al. 2006). The main advantage of these treatments over previous therapies lies
in the fact that they can be given at clinically relevant timepoints (24 and 48
hours post stroke for DTG and HUCBC respectively). In the permanent middle
cerebral artery occlusion (MCAO) model of stroke, injection of HUCBC (106) 48
hours (Newcomb et al. 2006) or administration of DTG (15mg/kg) 24 hours (Ajmo
Jr et al. 2006) after stroke reduces infarct volume by up to 80% when compared
to vehicle treated control. Originally both treatments were thought to decrease
infarct volumes by either reducing neuronal ion imbalances (DTG) (Katnik et al.
2006) or replacing neurons (HUCBC). Further studies have shown each of these
treatments had profound effects on components of the immune system.
HUCBC have been shown to migrate to injured brain and the spleen
(Vendrame et al. 2004). Subsequent studies showed that infiltration of the
HUCBC into the brain was not required for neuroprotection (Borlongan et al.
2004). Sigma receptors are also found in the spleen at high densities and are
expressed on lymphocytes and macrophages (Su 1991). The spleen is
important in ischemic pathology as splenectomy prior to stroke shows significant
reductions in neurodegeneration (Ajmo et al. 2008). T-lymphocytes in particular
are known to be present in the spleen in large numbers and to contribute to
stroke induced neurodegeneration (Offner et al. 2006; Yilmaz et al. 2006).
Peripheral immune cells such as these migrate to the infarct and interact with
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antigen presenting cells there to promote a proinflammatory immune response.
One of the principal immune cell types present in the infarct and known to serve
as antigen presenting cells is microglia (Morioka et al. 1993).
Microglia, the innate immune cells of the brain, are normally kept in a
quiescent ramified state (Streit 2002). Upon stimulation by dying neurons,
microglia become activated, assume an amoeboid phenotype, migrate to the site
of injury, and release inflammatory mediators (Gibson et al. 2005). Nitric oxide is
a particular noxious mediator generated by inducible nitric oxide synthase which
is upregulated in activated microglia which can interfere with neuronal respiration
and induce apoptosis. HUCBC and DTG have been shown to reduce microglial
activation in vivo (Ajmo Jr et al. 2006; Newcomb et al. 2006). DTG also
suppresses microglial activation by blocking calcium signaling and reduces
lipopolysaccharide (LPS) induced nitric oxide by this mechanism in vitro (Hall et
al. 2008).
The purpose of the present study was to determine whether the efficacy of
HUCBC and DTG in vivo at delayed timepoints is solely due to the impact on the
peripheral immune system or also involves direct effects on the ischemic brain
tissue. To study the effects of these therapies on ischemic tissue in the absence
of the peripheral immune system; organotypic hippocampal slice cultures were
subjected to oxygen glucose deprivation (OGD) in order to induce
neurodegeneration. Fluoro-Jade staining was used as a marker for degenerating
neurons, while nitric oxide production was used to identify microglia which had
differentiated into a neurodestructive phenotype.

93

Materials and Methods
Animal Care
All animal procedures were conducted in accordance with the NIH Guide
for the Care and Use of Laboratory Animals with a protocol approved by the
Institutional Animal Care and Use Committee at the University of South Florida.
Timed pregnant Sprague-Dawley dams were purchased from Harlan Labs
(Indianapolis, IN), maintained on a 12 hr light/dark cycle (7 am – 7 pm) and given
access to food and water ad libitum. Neonatal rats birthed from time-pregnant
dams were used for all experiments.
Organotypic Slice Culture
Organotypic slice cultures (OTC) were prepared using a method described
(Stoppini et al. 1991), with slight adaptations. Postnatal day 8-10 rat pups were
sacrificed by decapitation. Brains were removed and intact hippocampi were
isolated in ice cold isotonic buffer (136.89 mM NaCl, 5.37 mM KCl, 169 nM
Na2HPO4, 22.04 nM KH2PO4, 27.52 nM glucose, 59.01 mM sucrose). 400 µm
hippocampal slices were prepared using a McIlwain Tissue Chopper (Mickle
Laboratory Engineering Co. Ltd. Gomshall, Surrey, England). Only slices that
appeared thin and translucent were selected for culture. Slices were then
incubated for 90 min at 4˚C. Cultures were maintained on Millicell CM (Millipore
Corp., Billerica, MA) inserts and placed in 6-well plates containing Neurobasal
media supplemented with B27 and 5 mM L-glutamine. Slices were cultured for 14
days in room air supplemented with 5%CO2 maintained at 37˚C, receiving partial
media changes every 3-4 days prior to experimentation.
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Oxygen Glucose Deprivation
Organotypic slices were subjected to 48 hrs of normoxia or oxygen
glucose deprivation (OGD). Slices were assigned to 1 of 2 exposures (normoxia
or OGD) and 1 of 2 treatments (media, or HUCBC). Immediately prior to
exposure, inserts were transferred into new 6-well plates containing media, or
106 HUCBC (Sigma Aldrich, St. Louis, MO). Media consisted of Dulbecco’s
Modified Eagles Medium (DMEM; Mediatech, Herndon, VA) for normoxia or
DMEM without glucose (Invitrogen, Carlsbad, CA) for OGD. HUCBC (AllCells)
were thawed and resuspended in DMEM containing DNase (1ug/ml) to prevent
aggregation. HUCBC were washed twice and resuspended at a concentration of
108 cells/ml. HUCBC (106) were added to each well receiving treatment.
Cultures were maintained in a standard tissue culture incubator during the
normoxia exposure and a hypoxic chamber flushed with 1%O2, 5%CO2, and
balanced N2 (CBS Scientific Co. Inc., Del Mar, CA) held at 37˚C during the OGD
exposure.
Fluoro-Jade Staining
Organotypic slice cultures were stained with Fluoro-Jade (Histochem,
Jefferson, AR), which labels degenerating neurons. This method was adapted
from that originally developed (Schmued et al. 1997) and has been described by
Duckworth et al. (2005). Tissue was wet mounted and dried to glass slides.
Slices were rehydrated by then exposure to absolute ethanol for 3 min followed
by 70% ethanol and deionized water for 1 min each. Slices were oxidized using a
0.06% KMnO4 solution for 15 min followed by three rinses of double distilled
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water for 1 minute each. Slices were stained in a 0.001% solution of Fluoro-Jade
in 0.1% acetic acid for 30 min. Slides were again rinsed, allowed to dry at 45oC
for 20 min, cleared with xylene and cover slipped with DPX mounting medium
(Electron Microscopy Sciences, Ft. Washington, PA).
Nitric oxide imaging
Nitric oxide levels were measured using the NO sensitive dye, 4-Amino-5methylamino-2',7'-difluorofluorescein (DAF-FM). Organotypic slice cultures on
Millicell inserts were incubated for 1 hour at 37oC in DMEM (Mediatech)
containing 5μM DAF-FM (Invitrogen) and 0.1 % DMSO. The slices were washed
in PSS prior to NO measurements. DAF-FM loaded slices were imaged using a
DG-4 high speed wavelength switcher (Sutter Instruments Co., Novato, CA)
which applied excitation light at 488 nm. Emitted fluorescence light was collected
through the microscope objective (Zeiss; 2,5X Plan-Neofluar) and passed
through an emission filter (510 nm) onto a Cooke SensiCam CCD camera
(Cooke Corporation, Auburn Hills, MI). Images were recorded with Slidebook 3.0
software (Intelligent Imaging Innovations, Denver, CO). Nitric oxide levels were
calculated using the Slidebook 3 software. Fluorescent intensity was expressed
as arbitrary units.
Immunohistochemistry
Slice cultures were fixed with 4% paraformaldehyde in phosphate buffered
saline (PBS) at 4oC overnight. Slice cultures were removed from the MilliCell
inserts; wet mounted, and allowed to dry at 45oC for 1hr. The slides were rinsed
with PBS (pH 7.2), and placed in permeabilization buffer containing 10% goat
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serum, 3% 1M lysine, and 0.3% Triton X-100 in PBS for 1 hr at room
temperature. Next, sections were incubated overnight at 4°C in a PBS solution
with 2% goat serum and 0.3% Triton X-100 and primary antibody in a humidified
chamber, protected from light when necessary. Slides were washed with PBS (3
x 5 min) and incubated with a secondary antibody solution (PBS, 2% goat serum,
0.3% Triton X-100) in a humidified chamber protected from light. The sections
incubated with OX-42 mouse anti-rat (1:3,000, Serotec) were incubated with
Alexa-Fluor® 594 goat anti-mouse secondary (1:300, Molecular Probes) After
final washing the slides were cover slipped with Vectashield hard set mounting
media with DAPI (Vector Laboratories, Burlingame, CA).

Results
Oxygen glucose deprivation significantly increases neurodegeneration and
nitric oxide production in OTC.
In order to characterize the response of the OTC to OGD, slices were
subjected to varying OGD durations. The timepoints tested were 0, 12, 24, 36,
and 48 hours following induction of OGD. OTC were assessed for
neurodegeneration and nitric oxide production by staining with Fluoro-Jade and
DAF-FM, respectively. OGD induced significant increases in Fluoro-Jade
staining only in the 48 hour timepoint (p<0.05, n=4) as measured by one-way
ANOVA with post-hoc Dunnett’s test using 0 hour as a control (Figure 1A).
Significant increases in DAF-FM staining were seen in the 12, 24, and 48 hour
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timepoints (p<0.01, n=6) (Figure 1B). As the 48 hour timepoint had significant
increases in Fluoro-Jade and DAF-FM staining it was used for the remainder of
this study.

Figure 1. Oxygen glucose deprivation significantly increases
neurodegeneration and nitric oxide production in OTC.
Organotypic slice cultures were subjected to varying durations of oxygen glucose
deprivation. Neurodegeneration was assessed using Fluoro-Jade staining while
nitric oxide production was determined with DAF-FM. Graphs represent mean
stained area values +\- SEM for Fluoro-Jade (A) and mean stained intensity
values +\- SEM for DAF-FM staining (B). Asterisk denotes significance (p<0.05)
and (p<0.01) for (A) and (B) respectively as determined using one-way ANOVA
with post-hoc Dunnet’s test using 0hr as control. Scale bars represent 500μm
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HUCBC but not DTG significantly reduces Fluoro-Jade staining in OTC
following OGD.
Fluoro-Jade staining was used to identify neuronal damage in each of the
treatment groups. There was extensive Fluoro-Jade staining in all regions of the
slice cultures in the OGD group (Figure 2D) when compared to the normoxia
group (Figure 2A). DTG treatment (100μM) prior to OGD induction (Figure 2E)
failed to reduce Fluoro-Jade staining when compared to OGD alone (Figure 2D).
Administration of 106 HUCBC prior to induction of OGD reduced Fluoro-Jade
staining (Figure 2F). Normoxic samples treated with HUCBC (Figure 2C) and
DTG (Figure 2B) showed similar levels of Fluoro-Jade staining to the normoxic
controls (Figure 2A). To determine whether treatments caused a significant
decrease in neuronal death, levels of Fluoro-Jade staining were quantified.
Mean levels of Fluoro-Jade staining were significantly increased (p=<0.001, n=9;
Figure 2G) (p=<0.0009, n=10; Figure 2F) in the OGD treated sections when
compared to normoxic controls. DTG treatment did not significantly decrease
Fluoro-Jade staining when compared to OGD treatment alone (p=0.5119, n=9)
(Figure 2G). HUCBC treatment in OGD groups decreased Fluoro-Jade staining
significantly from the OGD control (p<0.05, n=6) (Figure 2G). Statistical
significance was determined by two-way ANOVA with post-hoc Bonferroni test.
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Figure 2. HUCBC but not DTG significantly reduces Fluoro-Jade staining in
OTC following OGD.
Photomicrographs depicting OTC under normoxic conditions treated with Vehicle
(A), 100μM DTG (B), and 106 HUCBC (C) or OGD conditions treated with Vehicle
(D), 100μM DTG (E), and 106 HUCBC (F). (G) Mean Fluoro-Jade positive areas
in DTG treated OTC showed no significant differences from vehicle controls in
either normoxia or OGD conditions. (F) Mean Fluoro-Jade positive areas in
HUCBC treated OTC showed significantly reductions in staining when compared
to vehicle controls in OGD but not normoxic conditions. Asterisks denote
significance (p<0.05) as determined by two-way ANOVA with post-hoc
Bonferroni’s test. Scale bars represent 500μm
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DTG treatment is ineffective in reducing Fluoro-Jade staining at multiple
concentrations.
There is likely a discrepancy in the concentrations of DTG between the in
vitro OTC and the in vivo MCAO models. Therefore, a concentration response
study was conducted to determine a concentration at which Fluoro-Jade staining
would be reduced following OGD (Figure 3). The concentrations of DTG used
were 0, 30, 100, and 300μM. This concentration range has been used to reduce
neuronal death and microglial activation in vitro. None of these concentrations
reduced Fluoro-Jade staining following OGD. The 300μM dose significantly
increased Fluoro-Jade staining when compared to OGD alone (139.22+/-14.34%,
p<0.001, n=6). As only HUCBC showed efficacy in reducing Fluoro-Jade
staining, only the effects of this treatment were explored with respect to NO
production.
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Figure 3. DTG treatment is ineffective in reducing Fluoro-Jade staining at
multiple concentrations.
Relative levels of Fluoro-Jade stained area in slices incubated in 0, 30, 100, and
300μM DTG prior to the induction of normoxia or OGD. No concentrations tested
decreased Fluoro-Jade staining; however, the 300μM DTG group subjected to
OGD had significantly increased Fluoro-Jade stained area compared to OGD
alone. Asterisk denotes significance p<0.001 as determined using one-way
ANOVA with post-hoc Dunnet’s test using 0μM DTG subjected to OGD as
control.

HUCBC treatment reduces DAF-FM staining in OTC following OGD.
The intracellular dye DAF-FM was used to determine the extent of NO production
in each of the treatment groups. There was robust NO production in all regions
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of the slice cultures in the OGD group (Figure 4C) when compared to the
normoxia group (Figure 4A). Administration of 106 HUCBC prior to induction of
OGD reduced NO production (Figure 4D). Normoxic samples treated with
HUCBC (Figure 4B) showed similar levels of NO production staining to the
normoxia controls. To determine whether HUCBC treatment caused a significant
decrease in NO production similar to that seen with the Fluoro-Jade staining,
levels of DAF-FM staining were quantified (Figure 4E). Mean levels of DAF-FM
staining were increased 172.01+/-75.21% in the OGD treated sections when
compared to normoxic controls. This increase was significant (p<0.05, n=3).
HUCBC treatment in OGD groups decreased DAF-FM staining 43.3+/-15.86%.
This decrease was significant from the OGD control (p<0.05, n=3). Significance
was determined by two-way ANOVA with post-hoc Bonferroni’s test.
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Figure 4. HUCBC treatment reduces DAF-FM staining in OTC following
OGD.
Photomicrographs depicting OTC under normoxic conditions treated with vehicle
(A), and 106 HUCBC (B) or OGD conditions treated with vehicle (C), and 106
HUCBC (D). (E) Mean DAF-FM intensities in HUCBC treated OTC showed
significantly reductions in staining when compared to vehicle controls in OGD but
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not normoxic conditions. Asterisk denotes significance (p<0.05) as determined by
two-way ANOVA with post-hoc Bonferroni’s test. Scale bars represent 500μm.

HUCBC reduces the number of nitric oxide producing microglia in ischemic
OTC.
Microglia and neurons can produce NO in response to ischemia. To determine
whether the observed NO production was due to activated microglia, DAF-FM
stained slices were also stained for the microglial marker CD11b. In the
normoxia slices NO production was observed in cells which did not exhibit
CD11b immunoreactivity (Figure 5A). In OGD treated slices NO production was
much more prominent and overlapped with CD11b staining (Figure 5C). HUCBC
treatment in both normoxia (Figure 5B) and OGD treated (Figure 5D) slices led to
similar patterns of staining which was indistinguishable from the normoxia
controls. Pearson’s correlation coefficient values from multiple images were
pooled and averaged to determine whether the signal overlap between the
CD11b and DAF-FM stains were significantly different between treatment groups
(Figure 5E). The Pearson’s correlation coefficient in the slices subjected to OGD
was significantly increased 140.21+/-46.99% when compared to normoxic control
(p<0.0012, n=6). HUCBC treatment of OGD slices significantly reduced the
Pearson’s correlation coefficient (p<0.01, n=7) such that it was not different from
normoxia controls (0.3819, n=5). Significance was determined by two-way
ANOVA followed by Bonferroni post-hoc test.
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Figure 5. HUCBC reduces the number of nitric oxide producing microglia
in ischemic OTC.
Confocal micrographs depicting OTC double stained with DAF-FM (NO)(green)
and CD11b (microglia)(red) under normoxic conditions treated with vehicle (A),
and 106 HUCBC (B) or OGD conditions treated with vehicle (C), and 106 HUCBC
(D). (E) Mean Pearson’s correlation coefficients demonstrated a significant
increase in staining overlap between the DAF-FM in OTC subjected to OGD
(p<0.0012). HUCBC treatment significantly reduced this overlap (p<0.01).
Asterisk denotes significance (p<0.05) as determined by two-way ANOVA with
post-hoc Bonferroni’s test. Scale bars represent 50μm
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Discussion
HUCBC and DTG have shown great promise in reducing ischemic
neurodegeneration at delayed timepoints following MCAO. The mechanisms by
which these treatments are neuroprotective are unclear. In vivo labeling studies
have shown that both HUCBC and DTG bind to the brain and spleen (Su et al.
1988; Vendrame et al. 2004). The spleen is a lymphoid organ which contains
peripheral lymphocytes which contribute detrimentally to the progression of
ischemic injury (Ajmo et al. 2008). There are both humoral and synaptic
crosstalk between the brain and the spleen via the HPA axis and the splenic
nerve, respectively (Elenkov et al. 2000). To determine whether DTG and
HUCBC have direct effects on the local microglial mediated inflammation and
neurosurvival in brain tissue in the absence of peripheral immune cells; an
organotypic hippocampal slice culture model of ischemia was utilized.
Organotypic hippocampal slice culture is a superior model for the study of
ischemic brain injury than dissociated neuronal or microglial cell cultures owing to
the fact that functional connections between different cell types are maintained
(Noraberg et al. 2005). In order to further characterize this model with respect to
neurodegeneration, slice cultures were subjected to OGD at different timepoints
and stained with Fluoro-Jade. In this model system neurodegeneration
increased in a time dependent manner following the induction of OGD with
significant increases observed at the 48 hr timepoint.
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The multiple inflammatory stimuli released by ischemic neurons in the
slice cultures activate microglia by a mechanism which mimics the in vivo
ischemic microenvironment more closely than traditional activators such as
lipopolysaccharide. Microglial activation is a hallmark of the neural response to
injury (Streit et al. 2004). Early stages of microglial activation, such as
phagocytosis of cell debris (Streit et al. 2005) and the release of growth factors
such as BDNF (Coull et al. 2005), can be neuroprotective. Further activation of
microglia can lead to the production of toxic pro-inflammatory cytokines (Dirnagl
et al. 1999; Rothwell 1996) and reactive oxygen species including nitric oxide
(Gibson et al. 2005). Nitric oxide can exacerbate the effects of ischemia on
neurons by competing for oxygen binding on cytochrome oxidase (Mander et al.
2005). Subsets of microglia, which produce high levels of nitric oxide, are likely
neurotoxic and deleterious in the ischemic microenvironment.
In this study the HUCBC treatment was neuroprotective but the DTG
treatment was not. This is intriguing as sigma receptor agonists reduce ischemia
and acidosis induced death in dissociated neuronal cultures by reducing calcium
influx into these neurons (Herrera et al. 2008; Katnik et al. 2006). Furthermore
sigma agonists suppress spreading depression and ionic imbalances in acute
hippocampal slice preparations (Anderson and Andrew 2002; Anderson et al.
2005). As spreading depression and calcium dysregulation are central
components of excitotoxic cell death, blocking these processes with DTG should
have resulted in reduced Fluoro-Jade staining in slices subjected to OGD. This
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demonstrates that in this model, excitotoxic cell death and anoxic depolarization
are not the primary mechanisms by which neurons die in this model.
Sigma receptors also have potent anti-inflammatory properties which can
reduce inflammation induced neuronal death. In the organotypic slice culture
microglia are the only immune cell type present. Sigma receptors reduce
microglial activation in vitro by suppressing intracellular calcium signaling (Hall et
al. 2008). By blocking intracellular calcium signals, many aspects of microglial
activation such as membrane ruffling, migration, and cytokine production are
impaired (Hall et al. 2008). The 300μM DTG concentration, which completely
suppressed microglial activation (Hall et al. 2008), resulted in the highest levels
of Fluoro-Jade staining encountered, suggesting that some aspects of microglial
activation are beneficial. This finding is in agreement with other studies which
have showed that ablation of microglia is neurodestructive(Lalancette-Hebert et
al. 2007).
Sigma receptor activation also suppresses T-cell mediated immunity by
upregulating production of the anti-inflammatory cytokine IL10 (Zhu et al. 2003).
As microglia can interact with T-cells as antigen presenting cells (Morioka et al.
1991), it is possible that modulation of this interaction by sigma receptor agonists
such as DTG could result in the robust neuroprotection seen in vivo. The results
shown here suggest that the neuroprotection mediated by DTG in vivo at delayed
timepoints is mediated by effects on systems outside of the CNS such as the
peripheral immune system.
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While HUCBC treatment has been shown to reduce propridium iodide
uptake in organotypic slice cultures, no studies have been performed to our
knowledge which directly measure neuronal damage or the ensuing inflammatory
response (Vendrame et al. 2005). Here we show that HUCBC can reduce both
neurodegeneration and microglial mediated inflammation. HUCBC are
composed of a mixture of cell types which are mainly leukocytes, with a small
(<1%) fraction of stem cells which are also present (Pranke et al. 2001). The
mechanisms by which HUCBC directly promote protection are unclear, but may
include the secretion of neurotrophic growth factors such as glial cell–derived
neurotrophic factor (GDNF), epidermal growth factor (EGF), brain-derived
neurotrophic factor (BDNF), and fibroblast growth factor (FGF) (Neuhoff et al.
2007). While cell to cell contact was prohibited by the membranes the slices
were grown on, secreted factors such as these growth factors could decrease
neurodegeneration.
HUCBC significantly decreased the number of microglia which expressed
NO. This is in agreement with the finding that HUCBC therapy in vivo
dramatically reduced the number of microglia present in the infarct (Newcomb et
al. 2006). Co-culture experiments in vitro demonstrate this effect is mediated by
the production of pro-inflammatory cytokines by CD8+ T-cells, which induce
microglial apoptosis following hypoxia (Jiang L 2006). Similar experiments using
a double transgenic PSAPP/Tg2576 mouse model of Alzheimer’s disease,
demonstrated that HUCBC can decrease microglial activation by reducing
CD40/CD40L interactions (Nikolic et al. 2008). Microglial CD40 is an important
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activation signal which is reduced by HUCBC treatment (Nikolic et al. 2008). As
HUCBC only decreased the incidence of NO producing microglia in the slice,
decreasing microglial CD40 expression may be a mechanism by which HUCBC
can cause this effect.
HUCBC and DTG are both potent suppressors of ischemia induced
neurodegeneration in vivo at delayed timepoints (Ajmo Jr et al. 2006; Vendrame
et al. 2004). Understanding the processes which these treatments modulate,
should shed light on the mechanisms for halting the pathophysiological effects of
ischemic injury. These studies show that sigma receptor activation on ischemic
brain tissue is not directly protective, suggesting that the target of this therapy is
peripheral to the CNS. A likely therapeutic target is the lymphocytes which
infiltrate the infarct at delayed timepoints (Gee et al. 2007). This interaction of
peripheral immune cells and injured brain tissue could also mediate the
protective effects of HUCBC seen in this study as they are composed primarily of
lymphocytes and monocytes (Pranke et al. 2001), and that migration into the
CNS is not required for this protection (Borlongan et al. 2004). Further research
into the effects of these treatments on the interaction between the CNS and the
peripheral immune system should yield further insight into the mechanisms by
which these two treatments reduce stroke induce brain injury.
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Chapter 4
The Spleen Contributes to Stroke Induced Neurodegeneration in an Indirect
Manner

A.A.Hall, D.D. Rowe, C.C. Leonardo, L.A.Collier, A.E.Willing, and
K.R.Pennypacker

Abstract
Stroke induced brain injury is the third leading cause of death and
disability in the United States. Recent studies have shown that the spleen plays a
major role in stroke pathology. Following stroke, the spleen becomes reduced in
size and cellular content. Our lab has shown that removal of the spleen prior to
MCAO reduces infarct volume by 80%. This study sought to characterize the
changes in spleen and brain over time following MCAO, and determine where
splenocytes migrate to influence neurodegeneration. To accomplish this, rats
received intrasplenic injections of the dye CFSE five days prior to MCAO surgery,
to label splenocytes. Rats were sacrificed at varying timepoints following MCAO
and brains and spleens were harvested for subsequent analysis. The spleens of
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animals were found to shrink by 24 hours post MCAO. This effect was transient,
with spleens regaining their size by 72 hours post MCAO. Numerous labeled
splenocytes were found in spleen, blood, and thymus. Very few splenocytes
were found in the brain and were restricted to blood vessels. To determine
whether the spleen influences the post stroke immune response by secreting
cytokines, IL10 and IFNγ levels were studied in the brain and spleen. IL10
expression was found to significantly increase in the spleen and brain by 96
hours post MCAO. This increase in IL10 and IFNγ expression was blocked after
treatments with HUCBC or DTG and likely reflects modulation of the immune
response mediated by these treatments.

Introduction
Local inflammation has both beneficial and deleterious effects on ischemic
lesions. When local inflammation activates the peripheral immune system,
however, a much larger inflammatory response is elicited causing collateral
destruction of the peri-infarct regions (Offner et al. 2006b). The brain
communicates with the immune system largely via direct innervation of lymphoid
tissues and humoral control provided by the hypothalamic-pituitary-adrenal axis
(HPA axis) (Chrousos 1995).
The thymus and the spleen become reduced in size (Offner et al. 2006b;
Vendrame et al. 2006) upon induction of CNS ischemia. Multiple groups have
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associated this decrease in thymus and spleen size with profound leucopenia
and an increased susceptibility to infection based on a lack of IFNγ producing Tcells (Prass et al. 2003; Yilmaz et al. 2006). This immunosuppression, while
likely helpful at reducing permanent brain injury, can be reversed by
administration of beta-adrenergic blockers such as propranolol (Meisel et al.
2005; Prass et al. 2006). The Offner group postulated that the decrease in
spleen and thymus size was due to mass apoptotic cell death based on TUNEL
immunoreactivity (Offner et al. 2006b). Recent work in our lab has demonstrated
that the spleen shrinkage is due, at least in part, to activation of alpha1
adrenergic receptors located on the smooth muscle capsule by circulating
catecholamines, and this shrinkage can be blocked by prophylactic
administration of prazosin, an alpha1 receptor antagonist (Ajmo Jr. CT 2009).
The induction of such profound immunosuppression indicates that the
peripheral lymphoid organs can exacerbate ischemic injury. The spleen in
particular plays a critical role in the response to ischemic injury and its treatment
at delayed timepoints. Splenectomy two weeks prior to stroke effectively reduces
infarct volume by 80% demonstrating a critical role for this organ in stroke
pathology. The importance of the spleen in stroke is also demonstrated by the
finding that human umbilical cord blood cells (HUCBC) injected into rats receiving
MCAO migrated primarily to the spleen and infarct (Vendrame et al. 2004).
HUCBC therapy restores both spleen size and cellular content when compared
to MCAO alone (Vendrame et al. 2005; Vendrame et al. 2006).
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The spleen can modulate the peripheral immune system by secreting
cytokines which can induce a pro-inflammatory (TH1) or anti-inflammatory (TH2)
immune response. Two important cytokines in this process are IFNγ and IL10.
IFNγ and IL10 induce TH1 and TH2 responses, respectively, and can serve as
surrogate markers for the inflammatory state following ischemia.
Experiments performed here characterized the post stroke immune
response with respect to the spleen over time. In this study, the shrinkage of the
spleen was shown to be a transient phenomenon. Splenocytes were found in the
blood and thymus, but only in very low numbers to the brain. Further analysis
demonstrated that IL10 and IFNγ levels are increased following stroke.
Treatment with DTG significantly decreased IL10 and IFNγ production in the
spleen. These experiments provide evidence that while the acute stress
response induces the production of IL10 it cannot completely suppress IFNγ
production. Treatment with DTG significantly reduces this pro-inflammatory
cytokine and decreases infarct volume.

Materials and Methods
Animal Care
All animal procedures were conducted in accordance with the NIH Guide
for the Care and Use of Laboratory Animals with a protocol approved by the
Institutional Animal Care and Use Committee at the University of South Florida.
Timed pregnant Sprague-Dawley dams were purchased from Harlan Labs
(Indianapolis, IN), maintained on a 12 hr light/dark cycle (7 am – 7 pm) and given
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access to food and water ad libitum. Neonatal rats birthed from time-pregnant
dams were used for all experiments.

Splenic injection of CFSE
CFSE injections were performed five days prior to MCAO by making a 4
cm dorsal midline skin incision at the caudal terminus at the level of the 13th rib.
Opening the abdominal wall on the anatomical left, 1.5 to 2.5 cm from midline
exposed the spleen. With blunt forceps, the organ, (with accompanying blood
vessels and adipose tissue), was exteriorized through the incision. CFSE (500μl
total volume in DMSO) was injected into 5 evenly spaced sites along the spleen.
The spleen was then reinserted into the animal and the wound was closed with
sutures.

Laser Doppler blood flow measurement
Laser Doppler Radar (LDR) was used to monitor blood perfusion (Moor
Instruments Ltd, Devon, England). A 2 mm diameter hole was drilled into the
right parietal bone (1 mm posterior and 4 mm lateral from bregma), and a guide
screw was set. The LDR probe (MP10M200ST; Moor) was inserted into the
guide screw, and the tip of the probe was placed against the pial surface of the
brain. Rats that did not show >55% reduction in perfusion during MCAO were
excluded from the study.
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Permanent Middle Cerebral Artery Occlusion
MCAO surgery was performed using the intraluminal method originally
described (Longa et al. 1989). Briefly, a filament (4cm long, 6lb test
monofilament) was advanced into the internal carotid artery by way of the
external carotid artery until it occluded the origin of the middle cerebral artery,
and tied off at the internal/external carotid junction to produce permanent
occlusion. The rat was then sutured, given a 1 ml subcutaneous injection of
saline, and allowed to wake in a fresh cage.

Brain Extraction and Sectioning
The animals were euthanatized with 0.5 ml of pentobarbital at 96 hours,
and perfused with saline and 4% paraformaldehyde. The brains were harvested,
post fixed in paraformaldehyde, and immersed in 20% followed by 30% sucrose
in PBS. Brains were frozen and sliced into 30μm sections with a cryostat.
Sections were either thaw mounted on glass slides or placed in Walter’s Antifreeze cryopreservative.

Fluoro-Jade Staining
Six coronal brain sections at 1 mm intervals were cut from 1.7 to -3.3 mm
from Bregma for infarct quantification. These sections were stained with FluoroJade (Histochem, Jefferson, AR), which labels degenerating neurons. This
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method was adapted from that originally developed (Schmued et al. 1997) and
has been described by (Duckworth et al. 2005). Sections were mounted and
dried to glass slides. Slides were rehydrated by then exposure to absolute
ethanol for 3 min followed by 70% ethanol and deionized water for 1 min each.
Slides were oxidized using a 0.06% KMnO4 solution for 15 min followed by three
rinses of double distilled water for 1 minute each. Slides were stained in a
0.001% solution of Fluoro-Jade in 0.1% acetic acid for 30 min. Slides were
rinsed, allowed to dry at 45 oC for 20 min, cleared with xylene and cover slipped
with DPX mounting medium (Electron Microscopy Sciences, Ft. Washington,
PA).

Infarct Volume Quantification - Fluoro-Jade stained tissue was digitally
photographed with an Olympus IX71 microscope controlled by DP manager
software (Olympus America Inc, Melville, NY) at a magnification of 1.25X.
Images were edited with Jasc Paintshop Pro. Area of neurodegeneration was
measured using the NIH Image J software. The area of the contralateral side of
the brain tissue was also measured and used to compensate for possible edema
in the ipsilateral hemispheres. Infarct volumes were then calculated by the
summation of the infarct areas.

Immunohistochemistry
The slides were rinsed with PBS (pH 7.2), and then placed in
permeabilization buffer containing 10% goat serum, 3% 1M lysine, and 0.3%
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Triton X-100 in PBS for 1 hr at room temperature. Next, sections were incubated
overnight at 4°C in a PBS solution with 2% goat serum and 0.3% Triton X-100
and primary antibody in a humidified chamber, protected from light when
necessary. Slides were washed with PBS (3 x 5 min) and incubated with a
secondary antibody solution (PBS, 2% goat serum, 0.3% Triton X-100,
biotinylated goat anti rat (1/300))for 1 hour followed by avidin / biotin /
horseradish peroxidase complex (Vectastain Elite ABC kit; Vector) for 1 h.
Sections were washed 3x in PBS, and metal-enhanced 3, 3’-diaminobenzidine
(Pierce, Rockford, IL) was used for color development.
ELISA assay
READY-SET-GO! ELISA kits (eBioscience) for IL10 and interferon-gamma
were used to determine levels of these cytokines. ELISAs were run according to
manufacturer’s instructions.

Results
Infarct volumes peak by 24 hours in rats subjected to MCAO
To characterize the progression of neurodegeneration following MCAO
infarct volumes were determined by Fluoro-Jade staining at various timepoints
following MCAO. The timepoints studied were 3, 24, 48, 51, 72, and 96 hours
post-MCAO. No Fluoro-Jade staining was observed in sham operated animals
or animals taken at 3 hours post MCAO. Fluoro-Jade staining reached peak
levels 24 hours post MCAO and remained elevated at all subsequent timepoints
(Figure 1).
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Figure 1. Infarct volumes peak by 24 hours in rats subjected to MCAO
Mean infarct volumes plotted over time following MCAO. Infarct volumes were
significantly increased from sham operated controls at the 24, 51, 72, and 96hour
timepoints. The three hour timepoint did not differ significantly from controls.
Asterisk denotes significance at p<0.05 as determined by one-way ANOVA with
a post hoc Dunnet’s test.

Post-stroke shrinkage of the spleen is a transient phenomenon
The spleen has been shown to shrink following MCAO. As the spleen
plays a critical role in infarct development, the size of the spleen was
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characterized over time. The timepoints studied were 3, 24, 48, 51, 72, and 96
hours post-MCAO (Figure 2). The spleen significantly decreased in size at the
24, 48, and 51 hour timepoints compared to sham operated or 3 hr MCAO
timepoint. The spleen regained its size by 72 hours post-MCAO such that it was
not different from the sham or 3 hr timepoint (p<0.01).

Figure 2. The spleen shrinks transiently following MCAO
Mean spleen weights plotted over time following MCAO. Spleen weights were
significantly decreased by the 24, 48, and 51hour timepoints. Spleen weights
were not significantly different from sham operated controls at the 3 72 and
96hour timepoints. Asterisk denotes significance at p<0.01 as determined by
one-way ANOVA with a post hoc Dunnet’s test using the sham operated animals
as controls.
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CFSE labeled splenocytes are present in various tissues following MCAO
To determine if the shrinkage in spleen size was associated with an
increase in spleen derived immune cells in the brain in vivo labeling of
splenocytes was performed. CFSE was injected into the spleens of animals five
days prior to MCAO to label splenocytes. Spleen (Figure 3A), blood (Figure 3B),
brain (Figure 3C), and thymus (Figure 3D) of animals at different timepoints were
assessed for CFSE positive cells. CFSE staining was abundant in all tissues
studied except brain, where CFSE stained cells were few and restricted to blood
vessels in the infarct.
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Figure 3. CFSE labeled splenocytes are present in various tissues following
MCAO
Representative sections from spleen (A), blood (B), brain (C), and thymus (D) at
96 hours following MCAO. CFSE staining was abundant in all tissues studied
except brain where CFSE stained cells were few and restricted to blood vessels
in the infarct.
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IL10 immunostaining is increased in the brain and spleen following MCAO
IL10 production in the infarct was characterized over time in MCAO
treated rats. IL10 immunostaining was performed on brain sections from 24
hours (Figure 4A), 51 hours (Figure 4B), 72 hours (Figure 4C), and 96 hours
(Figure 4D) following MCAO. Mean values plotted over time demonstrate a
significant increase in IL10 at the 96 hour timepoint compared to the 24 hour
timepoint (Figure 4E). Mean concentrations of IL10 in the spleen over time
(Figure 4F) demonstrate a significant (p<0.0?) increase in IL10 protein by the 96
hour timepoint. Mean concentrations of IFNγ in the spleen over time (Figure 4G)
demonstrate a significant increase (p<0.05) in IFNγ protein by the 96 hour
timepoint.
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Figure 4. IL10 and IFNγ expression increases over time following MCAO
Representative sections stained for IL10 from the 24 (A), 51 (B), 72 (C), and 96
(D) hour timepoints following MCAO. Mean IL10 immunostaining in brain plotted
over time (E) reveals a significant increase at the 96 hour timepoint. Mean
concentrations of IL10 in the spleen over time (F) demonstrates a significant
increase in IL10 protein by the 96 hour timepoint. Mean concentrations of IFNγ in
the spleen over time (G) demonstrates a significant increase in IFNγ protein by
the 96 hour timepoint. Asterisk denotes significance at p<0.05 as determined by
one-way ANOVA with a post hoc dunnet’s test using the 24 hour timepoint as
control.
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DTG or HUCBC treatment reduces IL10 and IFNγ following MCAO
As IL10 production is known to be induced by DTG and HUCBC therapies,
96hr timepoint brain sections from animals treated with vehicle (Figure 5A),
HUCBC (Figure 5B), or DTG (Figure 5C) were immunostained for IL10
production. Quantification of immunoreactivity demonstrated that IL10
production was significantly reduced (p<0.05) in animals treated with DTG and
HUCBC when compared to vehicle (Figure 5D). Mean concentrations of IL10
protein as measured by ELISA show that DTG treatment significantly decreased
IL10 production in the spleen (p<0.05) following MCAO (Figure 5E) Mean
concentrations of IFNγ protein as measured by ELISA show that DTG treatment
significantly suppressed IFNγ production in the spleen (p<0.05) following MCAO
(Figure 5F).
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Figure 5. DTG and HUCBC treatment reduces IL10 and IFNγ following
MCAO
Representative sections from animals treated with Vehicle (A), HUCBC (B), and
DTG (C) and sacrificed at the 96hr timepoint were immunostained for IL10
production. Quantification of immunoreactivity demonstrated that IL10
production was significantly reduced in the animals treated with DTG and
HUCBC when compared to vehicle (D). Mean concentrations of IL10 protein as
measured by ELISA shows that DTG treatment significantly decreases IL10
production in the spleen following MCAO (E). Mean concentrations of IFNγ
protein as measured by ELISA shows that DTG treatment significantly
suppressed IFNγ production in the spleen following MCAO (F). Asterisk
represents significance at p<0.05 as measured by one-way ANOVA with post
hoc Bonferroni’s test. Pound symbol indicated significance at p<0.05 as
measured by students t-test.
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Discussion
The peripheral inflammatory response to brain injury is tightly regulated.
IL1β, TNFα, and IL6 released in response to brain injury stimulate centers in the
locus ceruleus to induce neural sympathetic activation. Activity of these
cytokines also causes the release of CRH in the hypothalamus (Chrousos 1992).
Furthermore reciprocal activation can occur based on neural crosslinks between
the lateral paraventricular nucleus and the locus ceruleus (Saper et al. 1976).
Release of epinephrine from the adrenal glands in response to CRH, in
addition to the direct secretion of norepinephrine into the lymphoid organs by
sympathetic nerve fibers suppresses immune cell function and promotes the
release of TH2 cytokines such as IL10. Circulating catecholamines and
glucocorticoids alter the morphology of peripheral lymphoid organs known to be
involved in the progression of stroke, such as the spleen (Elenkov et al. 2000).
Experiments were performed to characterize the infarct and the size of the
spleen over time following MCAO. The infarct progressed rapidly from
essentially no infarction at three hours to 60% of the ipsilateral hemisphere being
infarcted by 24 hours. This is reflected in the spleen size as well, with spleens
not being significantly smaller than sham controls at 3 hours while decreased in
size by 30% by 24 hours. Interestingly, while infarct volume plateaued at levels
seen at the 24 hr timepoint, spleen weights were recovered by 72hrs such that
they were not different from controls. This suggests that the catacholaminergic
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stress response is a transient phenomenon which is counteracted by some
mechanism by 72 hours following MCAO.
As the change in spleen size has been associated with alterations in
splenic composition (Offner et al. 2006a), the cellular trafficking of splenocytes
into the brain was studied. Cells within the spleen were labeled with the cell
tracer CFSE prior to MCAO. While CFSE labeled cells were found in the blood,
spleen, and thymus, at no timepoint observed were labeled cells found in
appreciable numbers in the brain parenchyma. The only CFSE labeling
observed was restricted to blood vessels and the number of cells seen was less
than 10 per brain section. This was surprising as removal of splenocytes via
splenectomy reduces infarct volume by 80%. This suggests that the role of the
splenocytes in ischemic injury is indirect. One possible mechanism for
splenocytes to alter infarct volume without entering the brain is through antigen
presentation. It is known that dendritic cells home to the spleen upon activation
by antigen. As ischemic brain injury releases CNS specific antigens such as
myelin basic protein (MBP) and myelin oligodendrocyte glycoprotein (MOG)
dendritic cells could present these proteins to T-cells in the spleen and induce a
more potent inflammatory response. This theory is supported by studies using
mice deficient in T-cells which have markedly reduced infarct volumes (Yilmaz et
al. 2006), and in studies in which mice passively tolerized with MOG (Frenkel et
al. 2003) and MBP (Gee et al. 2008) show reduced infarct volumes .
If the response of the spleen to stroke is mediated by modulation of the
peripheral immune system, one mechanism by which this could be accomplished

135

is through the secretion of cytokines such as IL10 and IFNγ. These cytokines
can shift the immune system into a TH2 or a TH immune response, respectively.
Therefore, the final set of studies examined the production of cytokines over time
following MCAO. IL10 immunostaining was found to be markedly increased in the
infarct beginning at 51 hours and increasing significantly by 96hours. This
immunostaining was primarily neuronal in origin suggesting that these cells are
responding to inflammation by releasing this anti-inflammatory cytokine. IL10
can suppress the release of TNFα and IL1β (Chrousos 1995), so the observed
increases in the levels of this cytokine in the brain following MCAO may be
responsible for the return of the spleen size to sham control levels. IL10 and
IFNγ production both increased significantly in the spleen over time. This
suggests that there is an active inflammatory response which the body is trying to
suppress.
Interestingly, both HUCBC and DTG treatments significantly reduced IL10
and IFNγ levels in the brain. Both treatments are potently anti-inflammatory and
have been associated with increased IL10 production. This may be explained by
the fact that both treatments significantly decreased infarct volumes. If IL10
production was a response to inflammation mediated by such as IFNγ, then it is
logical that treatments which reduce this inflammation would reduce IL10
production in both the brain and the spleen.
Ischemic brain injury is a dynamic process. In this study, we characterized
the body’s response to ischemia over time. The observations gathered here lend
insight into the interplay between the brain and spleen in response to injury. As
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the peripheral immune system plays an important part in the body’s response to
ischemia, an understanding of how the spleen fits into this role is important to
identify therapeutic targets at delayed timepoints following MCAO
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Chapter 5
Conclusions

As our population ages and the quality of medical care improves, a greater
proportion of stroke victims survive. Many of these survivors are functionally
disabled, requiring assistance to perform basic tasks necessary for
independence. The costs to the survivor both financially and emotionally are
devastating. As two-thirds of stroke survivors are over the age of 65, most of
these survivors are enrolled in public medical programs such as Medicare. The
costs to these programs, and thus to the public, are enormous.
Currently there is only one FDA approved treatment for stroke, tissue
plasminogen activator (rTPA). This treatment yields significant improvements in
stroke outcome with a 13% increase in favorable outcome functionally in patients
eligible for this treatment. Therein lays the major caveat for this treatment. In
order to be eligible for rTPA, patients must get to the hospital, be diagnosed, and
have a CT scan to rule out hemorrhagic stroke within 3 hours of symptom onset
in order to be a candidate for therapy. Due to this very narrow therapeutic
window, only 3-5% of stroke sufferers are eligible for this treatment. Thus, there
is an immense need for therapies which can treat stroke effectively at delayed
(24-48hr), clinically relevant, timepoints.
The heady exuberance with which the stroke field embraced excitotoxicity
has largely been replaced with a painful hangover of failed clinical trials and
millions of dollars wasted. While it may be possible to treat stroke by reducing
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excitoxicity from a theoretical standpoint, from a clinical standpoint it is obvious
that these processes occur too early on for the patient to arrive for treatment in a
timely manner. The goal of stroke treatment now is to fundamentally alter the
body’s response to stroke and unlimber the potent innate repair mechanisms in
order to reverse ischemic brain injury and produce functional recovery. To
accomplish this it is imperative to look beyond the first 6 hours of ischemia and
gain a deeper understanding of the biology of ischemic injury at these delayed
timepoints. Essential to this is the identification of treatments which are effective
at delayed timepoints (24-48 hours post stroke). With such treatments it is then
possible to identify the systems through which they act to winnow out potential
targets for stroke therapy.
In order to treat stroke at 24 to 48 hours, it is as important to address the
immune response to the infarction as it is to treat the infarction it self. This can
be achieved in two ways: a cocktail of drugs targeting both inflammatory and
neurodegenerative processes, or a single treatment which has multiple effects
limiting both the immune response and neurodegeneration. As polypharmacy
treatment increases the propensity for side effects via drug-drug interactions; a
single therapy is more attractive for the treatment of patients in a frail state
induced by stroke.
Two such therapies which have shown promise in the MCAO model of
stroke are HUCBC and DTG. Both of these therapies reduce infarct volumes by
50% or more and are effective when administered 24hrs post MCAO. The
mechanism by which these therapies are neuroprotective is unclear. Both
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treatments decrease ischemic neuronal death and suppress inflammation in vitro
and decrease peripheral inflammation in vivo. As there are multiple systems
which could mediate the beneficial effects of these therapies, it is important to
identify which system is responsible for the observed reductions in infarct
volumes. The experiments described here sought to clarify whether these
therapies actively altered inflammatory processes in the CNS or the periphery
and the relative contributions of both sources of inflammation on ischemic
neuronal death.
It was clear from the studies performed in aim 1 that sigma receptor
activation reduces microglial activation at multiple levels, including the
morphological, migratory and inflammatory responses to several agents that
trigger these responses in microglia. The results of this study provide insight into
the role of sigma receptors in the regulation of immune system function. As
these processes are critical to the microglial response to injury, these findings
reveal a novel aspect of the modulation of microglial activation by sigma
receptors. Furthermore, these findings directly translate into effects this treatment
may have on other monocyte derived cells as well.
Blood born monocytes which are precursors to microglia and
macrophages can react to cellular debris generated by the initial ischemic insult
via activation of toll-like receptors. This can induce the transformation of these
monocytes into dendritic cells which can then present CNS antigens to
lymphocytes in the spleen and activate the adaptive immune system.

142

Invasion of peripheral macrophages is seen in ischemic injury beginning at
24hours and peaking by 3 days. In both cell types sigma receptor activation
likely reduces chemokine induced migration and activation of toll-like receptor
signaling in a similar manner to that seen with microglia.
Our results demonstrate that sigma receptor activation blocks changes in
actin aggregation in response to ATP application. Metabotropic P2Y12
receptors, which evoke increases in [Ca2+]i in microglia (Ohsawa et al. 2007), are
critical to the induction of membrane ruffling by ATP exposure (Honda et al.
2001). In our migration studies we saw robust migration in response to ATP
(which is mediated by P2Y12 receptors as well) and MCP-1, both of which
induce migration through a pertussis toxin sensitive Gi/o-protein (Dzenko et al.
2001; Honda et al. 2001; Sozzani et al. 1994). Migration induced by both
chemoattractants was inhibited by sigma receptor activation, suggesting that
sigma receptors inhibit migration either by direct interaction with the Gi/o-protein
or by interfering with downstream calcium signaling.
Chemokine signaling is a major mechanism by which local and peripheral
immune ells are recruited to sites of injury. Microglia, neutrophils, dendritic cells,
lymphocytes and monocytes all use chemokine gradients to migrate to sites of
injury. Inhibiting chemokine signaling downstream of the receptor is a powerful
mechanism by which sigma receptor activation can reduce immune cell
infiltration into the infarct.
P2Y12 receptors not only mediate ATP induced migration in microglia, but
they are also found on the surface of platelets where they promote adhesion and
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clot formation. Inhibition of platelet P2Y12 receptors via clopidogrel reduces the
formation of blood clots in patients at risk for stroke and myocardial infarction
(MI). As stroke and MI survivors are at an increased risk for a subsequent
stroke, inhibition of P2Y12 receptors on platelets by DTG would be not only
protective acutely but also prophylactically.
Activation of sigma receptors in the peripheral immune system has been
shown to potently suppress the inflammatory response to a variety of stimuli
(Bourrie et al. 2002). It was proposed that these anti-inflammatory effects were
mediated by sigma receptor-induced interleukin-10 (IL10) production (Zhu et al.
2003a). However, studies on sigma receptor-mediated immunosuppression in
RAW 264.7 macrophages suggested that IL10 is not always involved in these
responses (Gannon et al. 2001). This latter observation is consistent with our
finding that IL10 production in response to LPS treatment was decreased with
similar kinetics to reductions of TNF-α and NO production. This observation
implies that sigma receptor activation affects signaling upstream of protein
synthesis-dependent processes in the inflammatory response.
Sustained increases in basal intracellular calcium levels are integral to the
induction of the inflammatory response (Hoffmann et al. 2003) in microglia after
stimulation with LPS. Stimulation of toll-like receptors by LPS mimics the
stimulation of this receptor by cell debris which is present in the infarct. Sigma
receptor activation reduces the capacity of microglia to generate this sustained
increase in calcium in response to LPS.

This is associated with a decreased
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release of cytokines and NO. Reintroduction of calcium with ionomycin
overcame the sigma receptor activation induced blockade of NO production.
Our results in aim 1 show that activation of sigma receptors suppresses
microglial activation primarily by inhibiting calcium signaling. Calcium is a critical
signaling molecule in immune cells suggesting that the immunosuppressive
effects of this receptor are not necessarily restricted to only microglia.
Neurosteroids, such as progesterone and estrogen, bind to sigma receptors with
high affinity and are associated with decreased immune responsiveness (Su et
al. 1990). Our findings raise the intriguing possibility that these sigma ligands are
exerting central effects via the activation of sigma receptors (Su 1991). Since
astrocytes synthesize dehydroepiandrosterone (Zwain and Yen 1999), another
endogenous sigma ligand, the presence of sigma receptors on microglia may
represent a pathway by which microglial activation may be suppressed locally by
support cells.
Activated microglia have been associated with neurodegenerative disease
progression (Streit et al. 2004), and the presence of a significant number of
activated microglia has been linked to increased neuronal damage. In contrast,
ablation of microglia is also associated with increased damage (LalancetteHebert et al. 2007), which shows that microglia play a complex part in the
etiology of neurodegenerative disease. As microglia have the capacity to either
promote neurodegeneration or neurosurvival, the microglial response to injury is
a highly regulated process. Our findings support and expand upon the theory that
sigma receptors have potent immunoregulatory properties (Bourrie et al. 1995;

145

Bourrie et al. 2002). Interestingly sigma receptor activation in microglia has also
been associated with increased TGFβ production (Gekker et al. 2006). TGF-B is
an anti-inflammatory cytokine that is important in the induction of tolerance to
antigens. As circulating monocytes that encounter cell debris mature into antigen
presenting dendritic cells following MCAO, increased TGFβ signaling may impair
this process. Furthermore, TGFβ is known to enhance wound healing and

neurosurvival which could further explain the observed reductions in infarct
volume following MCAO.
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Figure 1. Sigma receptor agonists suppress microglial activation by
interfering with intracellular calcium signaling. Microglial activation is a
complex multi step process. Upon detection of a damage signal or invading
pathogen via chemoreception, a transient calcium increase occurs. Following
this, microglia rapidly rearrange their actin cytoskeleton and withdraw their
processes. They then migrate to the site of injury. Upon prolonged stimulation
the basal levels of intracellular calcium increase in the microglia, which
decreases their ability to generate the large calcium transients in response to the
chemoattractant serving as an endogenous stop signal. Once at the site of
injury, microglia can then release cytokines and reactive oxygen species
depending on the tissue microenvironment. Sigma receptor activation
suppresses the transient and sustained calcium increases necessary for these
processes, blocking microglial activation.
In aim 2 organotypic slice cultures were used to study the observed effects of
sigma receptor activation on microglia were neuroprotective in the absence of the
peripheral immune system. Organotypic hippocampal slice culture is a superior
model for the study of ischemic brain injury than dissociated cell cultures owing
to the fact that all brain cell types are present with functional connections
(Noraberg et al. 2005). The multiple inflammatory stimuli released by ischemic
neurons in the slice cultures activate microglia by a mechanism which mimics the
in vivo ischemic microenvironment more closely than traditional activators such
as lipopolysaccharide. In order to further characterize this model with respect to
neurodegeneration, slice cultures were subjected to OGD at different timepoints
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and stained with Fluoro-Jade. In this model system neurodegeneration
increased in a time dependant manner following the induction of OGD with
significant increases observed at the 48hr timepoint.
In this study the HUCBC treatment was neuroprotective but the DTG
treatment was not. This is intriguing as sigma receptor agonists reduce ischemia
and acidosis induced death in dissociated neuronal cultures by reducing calcium
influx into these neurons (Herrera et al. 2008; Katnik et al. 2006). Furthermore
sigma agonists suppress spreading depression and ionic imbalances in acute
hippocampal slice preparations (Anderson and Andrew 2002; Anderson et al.
2005). As spreading depression and calcium dysregulation are central
components of excitotoxic cell death, blocking these processes with DTG should
have resulted in reduced Fluoro-Jade staining in slices subjected to OGD. This
demonstrates that in this model, blocking excitotoxic cell death, anoxic
depolarization, and microglial activation directly is not sufficient to protect
neurons.
Intriguingly, similar effects are noted in vivo. Administration of
dehydroepiandrosterone, a potent sigma receptor agonist, reduced ischemic
infarct volume when administered 6-36 hours following stroke. When DHEA was
administered prior to or 1 hour after stroke it significantly increased
neurodegeneration. Both effects were found to be due to activation of the sigma1 receptor. Excitotoxicity associated phenomena such as NMDA receptor
activation are thought to occur within the first hour of stroke onset. Therefore it
seems unlikely that the prevention of excitotoxicity or the blockade of microglial
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activation is the mechanism by which DTG reduces infarct volume following
stroke.
Sigma receptors also have potent anti-inflammatory properties which can
reduce inflammation induced neuronal death. In the organotypic slice culture
microglia are the only immune cell type present. Sigma receptors reduce
microglial activation in vitro by suppressing intracellular calcium signaling (Hall et
al. 2008). By blocking intracellular calcium signals, many aspects of microglial
activation such as membrane ruffling, migration, and cytokine production are
impaired (Hall et al. 2008). The 300μM DTG concentration, which completely
suppressed microglial activation (Hall et al. 2008), resulted in the highest levels
of Fluoro-Jade staining encountered, suggesting that some aspects of microglial
activation are beneficial. This finding is in agreement with other studies which
have shown that ablation of microglia is neurodestructive (Lalancette-Hebert et
al. 2007).
While HUCBC treatment has been shown to reduce propidium iodide
uptake in organotypic slice cultures, no studies have been performed to our
knowledge which directly measure neuronal damage or the ensuing inflammatory
response (Vendrame et al. 2005). HUCBC treatment reduced both
neurodegeneration and microglial mediated inflammation. HUCBC significantly
decreased the number of microglia which expressed NO. This is in agreement
with the finding that HUCBC therapy in vivo dramatically reduced the number of
microglia present in the infarct (Newcomb et al. 2006). Similar experiments using
this model demonstrated that the MMP inhibitor AG3440 also reduced
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neurodegeneration in this model (Leonardo et al. 2009). MMP9 can reduce
neuronal viability directly by degrading the extracellular matrix and inducing
anoikis. As these treatments were given at the time of OGD it is unclear whether
these treatments reduced microglial activation directly or indirectly by reducing
neuronal death. Based on the data from DTG it seems likely that activated
microglia are not the cause but a byproduct of OGD induced neurodegeneration.
The studies from aim 2 show that sigma receptor activation on ischemic
brain tissue is not directly protective, suggesting that the target of this therapy is
peripheral to the CNS. Sigma receptor activation suppresses T-cell mediated
immunity by upregulating production of the anti-inflammatory cytokine IL10 (Zhu
et al. 2003b). As microglia can interact with T-cells as antigen presenting cells
(Morioka et al. 1991), it is possible that modulation of this interaction by sigma
receptor agonists such as DTG could result in the robust neuroprotection seen in
vivo. The results shown here suggest that the neuroprotection mediated by DTG
in vivo at delayed timepoints is mediated by effects on systems outside of the
CNS such as the peripheral immune system. A likely therapeutic target is the
lymphocytes which infiltrate the infarct at delayed timepoints (Gee et al. 2007).
This interaction of peripheral immune cells and injured brain tissue could also
mediate the protective effects of HUCBC seen in this study as they are
composed primarily of lymphocytes and monocytes (Pranke et al. 2001), and that
migration into the CNS is not required for this protection (Borlongan et al. 2004).
In aim 3, the systemic response to stroke was more closely studied.
Experiments were performed to characterize the infarct and the size of the
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spleen over time following MCAO. The infarct progressed rapidly from
essentially no infarction at three hours to 60% of the ipsilateral hemisphere being
infarcted by 24 hours. This is reflected in the spleen size as well, with spleens
not being significantly smaller at 3 hours than sham controls while by 24 hours
the spleen decreased in size by 30%. Interestingly while infarct volume
plateaued at levels seen at the 24hr timepoint spleen weights were recovered by
72hrs such that they were not different from controls. This suggests that the
catacholaminergic stress response is a transient phenomenon which is
counteracted by some mechanism by 72 hours following MCAO.
As the change in spleen size has been associated with alterations in
splenic composition (Offner et al. 2006), the cellular trafficking of splenocytes into
the brain was studied. Cells within the spleen were labeled with the cell tracer
CFSE prior to MCAO. At no timepoint observed were labeled cells observed in
appreciable numbers in the brain parenchyma.

This was surprising as removal

of splenocytes via splenectomy reduces infarct volume by 80%. This suggests
that the role of the splenocytes in ischemic injury is indirect. One possible
mechanism for splenocytes to alter infarct volume without entering the brain is
through antigen presentation. It is known that dendritic cells home to the spleen
upon activation by antigen. As ischemic brain injury releases CNS specific
antigens such as myelin basic protein (MBP) and Myelin oligodendrocyte
glycoprotein (MOG) dendritic cells could present these proteins to T-cells in the
spleen and induce a more potent inflammatory response. This theory is
supported by studies using mice deficient in T-cells which have markedly
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reduced infarct volumes (Yilmaz et al. 2006), and in studies in which mice
passively tolerized with MOG (Frenkel et al. 2003) and MBP (Gee et al. 2008)
show reduced infarct volumes .
The final set of studies examined the production of cytokines over time.
IL10 immunostaining was found to be markedly increased in the infarct beginning
at 51 hours and increasing significantly by 96hours. This immunostaining was
primarily neuronal in origin suggesting that these cells are responding to
inflammation by releasing this anti-inflammatory cytokine. IL10 can suppress the
release of TNFα and IL1β (Chrousos 1995), so the observed increases in the
levels of this cytokine in the brain following MCAO maybe responsible for the
return of the spleen size to the pre-stroke condition. IL10 and IFNγ levels in the
spleen also increased over time. As IFNγ is a very potent activator of
lymphocytes and macrophages, the fact that its levels increase over time
suggests that there is still an ongoing inflammatory response which the body is
responding to by upregulating IL10.
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Figure 2. Changes in spleen size and content over time reflect an evolving
interaction between the brain and immune systems following MCAO. The
spleen, by virtue of the α1-adrenergic receptors on its smooth muscle capsule
serves as a convenient maker of the acute stress response. Increased
circulating catecholamines bind to these receptors and cause the spleen to
substantially decrease in size between 3 and 24 hours following MCAO. These
same catecholamines act on β2-receptors located on circulating monocytes to
induce the release of IL10. Levels of splenic IL10 increase between 24 and 48
hours and remain elevated 96 hours post MCAO. IL10 reduces inflammation in
systemically which in turn causes the acute stress response to resolve. This
likely occurs between 48 and 72 hours following MCAO as the spleen regains its
previous size during this interval. Removal of the anti-inflammatory
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catecholamine signaling induces a rebound in pro-inflammatory IFNγ production
in the spleen.

HUCBC and DTG treatments significantly reduced IL10 levels in the brain.
Both treatments are potently anti-inflammatory and have been associated with
increased IL10 production. This disparity may be explained by the fact that both
treatments significantly decreased infarct volumes. If IL10 production by neurons
was a response to inflammatory damage, then it is logical that treatments which
reduce this inflammation would reduce neuronal IL10 production. IL10 and IFNγ
levels in the spleen were also significantly inhibited by DTG 96 hours post
MCAO. This likely reflects the fact that the majority of catecholamine induced
IL10 is produced by monocytes (Woiciechowsky et al. 1998), a process which is
inhibited by DTG (Hall et al. 2008).
Taken together the data presented here present an interesting view of
stroke induced injury and the relative contributions of the various factors
involved. Following the initial induction of ischemia excitotoxic processes
damage neurons. These neurons are protected from immediate neuronal death
by the concerted actions of microglia and astrocytes. If recanalization can be
achieved at this point (such as with rTPA administration) the total damage can be
significantly reduced. This is effective out to approximately 6 hours following
occlusion. After this time, inflammatory cytokines induce the acute stress
response via HPA axis activation. This response causes the spleen to shrink
and reduces TH1 immune responses. TH2 responses such as IL10 production
154

increase starting at 24 hours in the spleen and brain. IL10 is released rapidly
from blood borne monocytes following β2-adrenergic receptor stimulation
(Woiciechowsky et al. 1998). This anti-inflammatory cytokine likely acts on brain
centers in the hypothalamus and brain stem to shut down the acute stress
response by 72 hours. The decreased catecholamine signaling allows the spleen
to regain its size and removes the tonic immunosuppressive stimulus on
circulating lymphocytes. These lymphocytes have likely been migrating to the
infarct and interacting with antigen presenting cells in the spleen and brain. In
the absence of the stress response, these cells begin producing TH1 type
cytokines. In the spleen this is reflected by the rebound in IFNγ seen between 48
and 96 hours post MCAO. This correlates with increased IL10 expression in the
brain but not with a second induction of the acute stress response. This implies
that the inflammatory signaling at this time point is not mediated by TNFα, IL1β,
and IL6. This second inflammatory response is likely a T-cell mediated event
and likely leads to the cell mediated clearance of compromised neurons from the
infarct.
DTG and HUCBC likely interfere with the ability of the peripheral immune
response to continue following cessation of the acute stress response. HUCBC
can not only suppress inflammation but can also interrupt the acute stress
response leading to early recovery of spleen weight. The therapeutic target for
DTG is likely T-cells which upon sigma receptor activation switches from a TH1
(IFNγ producing) to a TH2 (IL10 producing) phenotype. Sigma receptor
activation likely suppresses macrophage and monocyte function similarly to
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microglia. T-cells, however, have been implicated as the cell type which are
necessary for ischemic injury (Yilmaz et al. 2006).

Implications and Future Directions
The immune system is a promising target for the treatment of stroke
induced brain injury. The results from this set of studies further clarify the role of
the immune system in ischemic brain injury, and the mechanisms by which
delayed treatments for stroke function. Timing of immunomodulatory therapies is
critical for their success. HUCBC therapy is good example of this, HUCBC must
be transplanted during the acute stress response for efficacy (Newcomb et al.
2006). DTG likely has a similar requirement, as sigma receptor activation by
DHEA is neuroprotective when administered at delayed (6-36 hour) but not
hyperacute (<1 hour) times following ischemia (Li et al. 2009). By studying
HUCBC and DTG, and their effects on ischemic injury both in vivo and ex vivo, it
was possible to determine that microglial activation following ischemic injury is
not necessarily deleterious in the absence of the peripheral immune response.
This perhaps explains why in a splenectomized animal there is a greatly reduced
infarct. Rats lacking a spleen still have activated microglia in their infarcts,
however by 96 hours these cells become ramified and likely do not contribute to
neuronal death (Ajmo et al. 2008).
Furthermore, as DTG was neuroprotective only in the presence of the
peripheral immune system suggests that modulation of this system is an ideal
target for the treatment of stroke at delayed timepoints. It is likely that while
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HUCBC are neuroprotective in the absence of the peripheral immune system,
their main mechanism for action is also on the peripheral immune system. Three
facts support this contention: 1, HUCBC are more effective when administered
intravenously than when administered intrastriataly, 2, HUCBC are most
efficacious at 48 hrs a timepoint at which the peripheral immune system is
actively infiltrating the brain, and 3, HUCBC do not further decrease infarct
volume in splenectomized rats suggesting that the direct effects of HUCBC on
the ischemic brain tissue is minimal.
Further studies will be needed to fully understand the role of the peripheral
immune system at delayed timepoints following stroke. One such study would be
therapeutic splenectomy. If splenectomy surgery 24 hrs post stroke was as
efficacious as two weeks prior to stroke, it would demonstrate that excitotoxic
processes are not as damaging as previously thought. As these processes are
still actively being targeted for stroke therapy, the results of this type of study
would help refine future stroke therapies and improve the success rate in stroke
treatment.
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Figure 3. Successful therapeutic targets change as the body’s response to
stroke changes over time. The most important concept in stroke treatment is
that stroke therapies must be applied at the proper stage in of the disease state.
Therapies which are effective at reducing excitotoxicity or preventing infiltration of
the parenchyma are likely are only going to be of benefit very early on in the
disease progression, prior to the induction of the inflammatory response.
Likewise administrations of anti-inflammatory treatments are not likely to be of
benefit prior to the induction of the acute stress response. This is because the
acute stress response is neurologically protective and is induced by proinflammatory cytokines. Finally treatment for stroke at extremely delayed
timepoints (>72 hrs) is likely to be limited to rehabilitation therapies which use
various stimuli to promote axonal regeneration and partial gain of function.
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